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FRET-BASED INVESTIGATIONS OF THE STRUCTURE-FUNCTION
RELATIONSHIPS IN THE NMDA RECEPTOR
Abstract
Drew Matthias Dolino, B.S.

Advisory Professor: Vasanthi Jayaraman, Ph.D.

The N-methyl- D -aspartate (NMDA) receptor is one member of a class of
proteins known as the ionotropic glutamate receptors. Ionotropic glutamate
receptors mediate the majority of excitatory neurotransmission in the central
nervous system, with the NMDA receptor standing out among these
receptors for its requirement of a co-agonist, its magnesium-block-based
coincidence detection, its slow kinetics, its calcium permeability, its
allosteric modulation, and its especially important functional roles in
synaptic plasticity, excitotoxicity, and more. In recent years, a wealth of
structural information has come about describing endpoint structures to
high resolution, but such structures are unable to fully resolve the
movements and dynamics necessary for appropr iate function. The work in
this dissertation uses single molecule Förster Resonance Energy Transfer
(smFRET) as a means to address that gap. We have examined the question of
partial agonism of the NMDA receptor, noting a mechanism of a dynamically
graded cleft closure. We have pushed the bounds of the temporal resolution
vii

of such methods and been able to resolve fast dynamics of the ligand -binding
domain, noting the adherence of the domain to the conformational selection
model, and the revelation of a novel conformation leading to activation
hitherto unknown. Finally, we have also directly examined the
conformational dynamics of the transmembrane domain of the NMDA
receptor with regards to its gating motions, granting unprecedented insight
into the movements of the ion channel domain and elucidating a novel
mechanism of allosteric inhibition. Such biophysical characterization of the
NMDA receptor is essential, not only simply to know how the receptor
works, but also to develop effective therapeutics that do no t impair the
receptor’s important physiological roles.
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Chapter 1: Introduction to NMDA Receptors and post-synaptic function
N-methyl-D-aspartate (NMDA) receptors are one member of a family of
proteins known as the ionotropic glutamate receptors (iGluRs). These iGluRs, which
also consist of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and
kainate receptors, are ligand-gated ion channels that mediate the majority of fast
excitatory neurotransmission in the central nervous system (1). Because of this
important role, NMDA receptors are implicated in behavior, cognition, and neural
development, as well as in learning and memory. Conversely, dysfunction of NMDA
receptors is similarly implicated in various neurological disorders such as depression,
stroke, schizophrenia, epilepsy, and Alzheimer’s disease (1-3).
Over the last decade and a half, a number of high-resolution crystal and cryoEM structures have been published on the NMDA receptor, starting from the original
studies of isolated domains (4-8) and eventually culminating in the structures of the
‘full-length’ NMDA receptor (9-12). However, these structures, though they have
verified and expanded upon decades of previous structure-function studies, still leave
many questions unanswered, especially with regard to the dynamic motions of the
proteins. To address this gap, the work presented in this dissertation aims to examine
the dynamic movements and conformational changes undergone by functional NMDA
receptors and to synthesize the spectroscopic, structural, functional, and biochemical
data available to clarify the mechanisms by which NMDA receptors activate and gate.
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Summary of NMDA receptor functional significance
As mentioned above, the iGluRs are the main mediators of fast excitatory
neurotransmission in the central nervous system (CNS). Briefly, when an excited
neuron releases the neurotransmitter glutamate and the glutamate subsequently binds
an iGluR, this binding event leads to a conformational change that results in the
formation of a cation-permeable pore within the iGluR. Cations—typically sodium,
potassium, and sometimes calcium (depending on the particular receptor)—flow
down their electrochemical gradient through that pore, generating a net inward
current (inward movement of cations, measured as negative amperes), a
depolarization of the resting negative membrane potential toward zero and even
toward positive millivolts, and the propagation of the excitatory signal (13). Other
neurotransmitters exist, both excitatory and inhibitory, but glutamate remains the
major excitatory receptor in the CNS, and thus glutamate’s importance, as well as the
importance of the iGluRs, to neurophysiology and neuropathology remains
paramount.
Among the iGluRs, NMDA receptors hold a special role, such that the iGluR
family is often divided into two classes: NMDA receptors and non-NMDA receptors
(1). The features that distinguish NMDA receptors are myriad and include (i) voltagedependent pore-block by magnesium (14, 15), (ii) a much higher calcium permeability
relative to other iGluRs (16), (iii) slower gating kinetics (17-19), and (iv) the
requirement of a co-agonist such as glycine (20) or D-serine (21) in order to activate
the channel. These special features speak to the particularly important role of NMDA
receptors to several cellular models of learning and memory (1).
2

NMDA receptor-dependent long-term potentiation (LTP) and long-term
depression (LTD) are two such examples of NMDA-receptor mediated synaptic
plasticity as a means to describe memory (22). LTP is a phenomenon by which
neurons remodel a specific synapse to strengthen the effect of a future stimulus. The
release of neurotransmitters from a single action potential alone is unlikely to elicit a
robust NMDA-mediated response. Though glutamate and its co-agonist bind to the
NMDA receptor, ion permeation through the receptor is inhibited by magnesium ions
held in the pore by negative membrane potentials (14, 15). Instead, non-NMDA
receptors such as the AMPA receptor provide the bulk of the initial spike of
depolarization. With strong or frequent stimulation, though, the depolarization from
non-NMDA-receptor sources can build up, allowing for the ejection of magnesium
from the NMDA receptor pore and the ability of the NMDA receptor to experience a
robust opening upon binding of its agonists (14, 15). This requirement of concurrent
depolarization and agonist binding has led to NMDA receptors being described as
coincidence detectors (1). Subsequent entry of calcium through activated NMDA
receptors can then signal a series of downstream processes that lead to synaptic
remodeling. In one example pathway of NMDA-receptor-mediated LTP, the calciumtriggered activation of kinases such as calcium/calmodulin-dependent kinase II
(CaMKII) (23), among others (24-27), leads to phosphorylation of AMPA receptors,
resulting in increased conductance and in increased transport to the synaptic
membrane (28-30) in the early phase of LTP expression. Later phases, more
dependent on downstream protein expression, manifest in such ways as spinal
enlargement and increased spinal density (22). Conversely, weak or slow-frequency
3

stimulation of NMDA receptors leads to LTD and the weakening of the synapse. As
LTP was largely kinase-mediated, LTD seems to prefer the activation of protein
phosphatases such calcineurin and protein phosphatase 1, which have higher
calcium/calmodulin affinity than CaMKII to allow for their activation despite the
weaker calcium signal (22, 31-34).
Experimentally, LTP and LTD can be reliably induced by tetanic highfrequency stimulation (e.g. 100 Hz for 1 sec) and slow-frequency stimulation (e.g. 1 Hz
for 10 min), respectively (22). Physiologically, spike timing-dependent plasticity
(STDP) has gained ground as a more plausible model for LTP and LTD induction.
With STDP, the synchrony of the synaptic input and post-synaptic action potential
generation determine the propensity of the synapse to undergo either LTP or LTD,
with pre-synaptic stimulation about 5-20 ms prior to post-synaptic action potential
generation tending toward induction of LTP (35-37). Mechanistically, this pre-leadingpost spike order allows for calcium-entry from back-propagating action potential
(bAP)-activated voltage-dependent calcium channels (VDCCs) to combine
supralinearly with NMDA receptor-mediated calcium entry, whose peak is delayed
from the pre-synaptic signal due to the slow kinetics of magnesium unbinding (38)
and the aforementioned slow kinetics of activation and deactivation (1). A postleading-pre spike order, conversely, will lack this synergistic calcium response and
may even result in a lower-than-baseline calcium signal due to calcium-dependent
inactivation (see below) of the NMDA receptors from bAP-mediated VDCC activation
(39). Consistent stimulation of the postsynaptic neurons in this order thus tends to
lead to NMDA-receptor dependent LTD (35-37).
4

Though the above introduction focuses mainly on their post-synaptic effects,
NMDA receptors are also located pre-synaptically (40, 41), extra-synaptically (42-45),
and non-neuronally (46), where they serve a variety of roles, from pre-synaptic
expression of plasticity (47), neuronal synchrony (48), and excitotoxicity (44, 49), to
vasodilation (50, 51), glomerular filtration (52, 53), gustatory sensation (54, 55), and
more (46). These roles underlie the importance of understanding the structural and
biophysical mechanisms of NMDA receptor function as from this understanding,
better treatments targeting pathologically aberrant dysfunction whilst maintaining
NMDA receptor physiological roles can be developed (56).

5

Chapter 2: Structure of NMDA Receptors
NMDA receptors are obligate hetero-tetramers consisting of two glycine- (or Dserine-) binding GluN1 subunits and two other subunits, typically either glutamatebinding GluN2 (spanning GluN2A through GluN2D) or, less often, glycine- (or Dserine-) binding GluN3 (GluN3A and GluN3B) (17, 57). Though tetrameric, NMDA
receptors and other iGluRs arrange in a 1-2-1-2 organization as a dimer of
heterodimers and thus show pseudo-two-fold symmetry (58) (Figure 1). Each
individual subunit has a modular architecture with distinct structural and functional
domains: the extracellular amino-terminal domain (ATD), the extracellular ligandbinding domain (LBD) (also called the agonist-binding domain, ABD), the
transmembrane domain (TMD), and the intracellular carboxyl-terminal domain
(CTD) (1). Interestingly, subunit dimer pairing is not consistent throughout the length
of the protein—the NMDA receptor and the other iGluRs undergo domain swapping,
wherein a subunit will dimerize with one neighbor at the level of the LBD, and the
opposite neighbor at level of the ATD (9, 10). Between each domain within a subunit,
there are linkers connecting the distal and proximal domains, which seem to serve as
sites through which tension induced from conformational changes in one domain is
transmitted to the others (59-63). The structure and function of each domain will be
further discussed below.

6

Amino-Terminal Domain

Agonist-Binding Domain

Transmembrane Domain

Carboxyl-Terminal Domain

Figure 1. Overview of NMDA Receptor structure
The NMDA receptor is an obligate heterotetramer, typically consisting of two
GluN1 (yellow and blue) and two GluN2 (red and green) subunits. Each subunit has a
modular arrangement, with distinct functional and structural domains (labeled). The
carboxyl-terminal domain has yet to be structurally elucidated.

7

Amino-Terminal Domain
The ATD layer of the NMDA receptor is the more distal of the two extracellular
domain layers (Figure 1). It is typically the largest domain of each subtype and among
the most diverse (1). Further, the ATD confers many of the subunit-specific properties
among different NMDA receptor subunits. Chimera-swapping experiments in which
individual domains of GluN2 subtypes were switched for the equivalent domain in a
different subtype largely exhibit the property of the subtype to which the ATD, and
especially the ATD-LBD linker, belonged (64, 65). However, these same studies also
use GluN2 ATD-deletion mutations to show that the GluN2 ATD is not essential to
form functional receptors in recombinant systems (64, 65). Conversely, the GluN1
ATD does seem to be essential to tetramer assembly (66) and function. ATDs from all
subunits, though, do participate in regulation and allosteric modulation of the NMDA
receptor and may also participate in the binding of extracellular proteins (67, 68).
Overall, the NMDA receptor ATD is organized into a bi-lobed clamshell-like
structure (7), similar to the LBDs (discussed below). When describing the domain, it is
often subdivided into the two lobes that comprise it: the upper lobe, known as
regulatory domain 1 (R1); and the lower lobe, known as regulatory domain 2 (R2) (69).
As these names imply, these domains play important roles in regulation and allosteric
modulation of the NMDA receptor. This is in stark contrast to the AMPA receptor, in
which the ATD seems to play mainly a structural and organizational role (1). This
ability of the ATD to affect function may be a result of increased interaction and interdigitation seen between the ATD and LBD layers of the NMDA receptor as compared
to that of the AMPA receptor (9, 10, 70). Both positive and negative allosteric
8

modulation of the NMDA receptor is facilitated by ATD interactions and, as will be
discussed below with the LBD, this modulation is intimately tied to the closure or
opening of the ATD clamshell cleft (71-73).
As mentioned previously, the GluN2 ATD plays a large role in the properties of
the receptor as a whole, with chimeras swapping the ATD and its linker also swapping
receptor open probability (Po), response time course, and agonist potency (64, 65,
74). The differing effects of the ATDs on receptor function may be partially explained
by the resting conformations of the ATDs: GluN2A, which has a more open ATD,
allows for a larger open probability (around 0.5) than GluN2B, which has a more
closed ATD (open probability around 0.1) (71, 73, 74). Such a relationship occurs
because closure of the ATD cleft, via a raising of the lower lobe R2, results in an
increase in tension in the linker connecting it to the LBD, destabilizing the LBD dimer
interface that maintains an open channel (see below). Different allosteric modulators
of the NMDA receptor also exploit this relationship by inducing or reducing ATD cleft
closure to regulate channel activity. Zinc cations are endogenous modulators (75) that
bind to a series of histidine residues between the upper and lower lobes of the ATD
(76-78). Two additional histidine residues in particular play an important role in
coordinating the high-affinity nanomolar binding of zinc to GluN2A, which may
explain why the other GluN2 subunits show lower affinity micromolar binding (76, 77,
79, 80). The positioning of these coordinating histidines within and toward the outer
end of the ATD domain cleft (7) was expected, given the ability of zinc to induce ATD
cleft closure (71), but interestingly, the synthetic antagonist ifenprodil, which via
homology to bacterial periplasmic binding proteins as well as by functional studies
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(81) was predicted to also bind within the GluN2B ATD cleft, instead binds to the
interface of the GluN1 and GluN2B ATD subunits (8). Despite this surprising
localization, ifenprodil also induces ATD cleft closure, as first shown by Luminescence
Resonance Energy Transfer (LRET) experiments (73), and subsequently confirmed by
cryo-EM microscopy (11).
As ATD-mediated inhibition proceeds via a closure of the ATD cleft, ATDmediated potentiation of NMDA receptors was hypothesized to proceed by an ATD
cleft opening. Indeed, spermine is an endogenous polyamine that potentiates GluN2Bcontaining NDMA receptors (82, 83). Similar to ifenprodil, spermine binds at the
interface between GluN1 and GluN2B ATD subunits (84), but in this case induces an
opening of the ATD cleft (72). This potentiation by spermine and other polyamines is
absent in NMDA receptors with GluN1 splice variants containing the polybasic exon 5,
indicating that it is an electrostatic interaction between the polycationic spermine or
exon 5 with the anionic lower R2 lobes of the NMDA receptor ATDs that pulls those
lower lobes together to potentiate the channel.

Ligand-Binding Domain
The ligand-binding domain layer is the more proximal of the two extracellular
domain layers of the NMDA receptor (Figure 1). As the name suggests, the LBD binds
ligands, more specifically the agonists required to activate the channel (hence the
LBD’s other name—the agonist-binding domain). The GluN2 subunits bind
glutamate, meriting the NMDA receptor’s place among the glutamate receptors. The
GluN1 and GluN3 subunits, however, bind a different co-agonist that is also required
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for channel activation. The first full agonist known to activate these subunits was
glycine (20), but since then D-serine has also been identified as another
physiologically relevant full agonist (85, 86). The physiological relevance and
distinction between the two full agonists has been debated, but it is now generally
believed that D-serine is the main synaptic co-agonist while glycine acts more as an
extrasynaptic agonist for NMDA receptors (87). This distinction is not universal,
however, and glycine does remain the synaptic neurotransmitter at certain synapses
(88). With this in mind, glycine, as the first identified co-agonist as well as the
cheaper of the two GluN1 full agonists, has been the preferred co-agonist of choice for
the GluN1 subunit for biophysical characterization, and GluN1 and its binding site will
be hereafter described as glycine-binding.
As with the ATD, the LBD also folds as a bi-lobed clamshell-like structure (46). Unlike the ATD, the sequence encoding the NMDA receptor LBD is interrupted by
two membrane-spanning helices (M1 and M3), as well as a re-entrant membrane loop
(M2) (1, 9, 10). Thus, the LBD has been subdivided in two ways: by primary sequence
(S1 and S2—sequence before and after the transmembrane sequences, respectively),
and by tertiary folding (D1 and D2—upper and lower lobe, respectively). Much of the
early work on the NMDA receptor LBDs has been performed on the isolated LBD,
where S1 and S2 have been joined by a short glycine-threonine dipeptide linker (4-6,
89-91). These studies, as well as LRET studies on full-length receptors (92) have
confirmed that the LBDs undergo a cleft-closure conformational change upon
introduction of full agonists. Similarly, locking the LBD cleft closed via formation of
disulfide bridges can also activate the channel in the absence of agonist (93). Cleft
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closure is mediated by the raising of the D2 lobes, inducing a tension on the linkers
between the LBD and TMD, which eventually pulls the channel open (59). During this
process, the LBD heterodimers stay intact through the D1 lobes, but under prolonged
tension, the heterodimeric interface breaks, the dimer ruptures, and the receptor
desensitizes (94).
Though full agonists have been shown to activate NMDA receptors by fully
closing the LBD cleft, until the work of this dissertation the mechanism of how partial
agonists partially activate the NMDA receptor has been unclear. Studies on the AMPA
receptor produced a strong correlation between the degree of AMPA receptor LBD
cleft closure and extent of AMPA receptor activation with the structures of partial
agonists showing the cleft in an intermediate conformation of partial cleft closure (9597). With the NMDA receptor, especially with the GluN1 glycine-binding domain, this
relationship was not seen. Crystal structures of both full and partial agonists
crystallized in the same conformation (4, 6). Experiments using ensemble LRET
measurements were able to identify a state of partial cleft closure at the glutamatebinding GluN2 LBD, but again no resolvable difference in the GluN1 LBD could be
distinguished (92). The exploration of this question and the mechanism of partial
agonism at the GluN1 subunit will be the subject of Chapters 4 and 5.

Transmembrane Domain
Though the ATD and LBD control the timing of channel activation, it is
through the transmembrane domain of the NMDA receptor that the ions actually flow
in order to give the receptor most of its functional significance. The overall structure
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of the TMD shows pseudo-fourfold symmetry and is arranged similar to an inverted
potassium channel (98), although NMDA receptors have an extra M4 membranespanning helix which interacts with the neighboring M1 (9, 10). At the extracellular
entrance to the pore, forming the linker between the C-terminal end of the pore-lining
M3 helix of the GluN1 subunit and the LBD, is a DRPEER motif (63), which seems to
confer an electronegative patch that facilitates calcium influx and conductance by
attracting calcium to the area. Just proximal to the DRPEER motif is the Lurcher motif
SYTANLAAF, forming the extracellular side of the M3 helix. Mutations in this helix
have been shown to produce constitutively active channels; correspondingly, the
elucidation of full-length structures has shown this motif to form the first and
narrowest constriction in the ion channel (9, 10). Below this constriction is a waterfilled central vestibule, followed by another constriction formed by the apex of the M2
pore loop (9, 10). This apex, which in GluA2 AMPA receptors harbors the Q/R editing
site in GluA2 AMPA receptors that is responsible for calcium impermeability (99,
100), contains an asparagine in NMDA receptors whose identity is crucial for
maintaining calcium permeability as well as magnesium block (101).
Importantly, the structural studies of the transmembrane domain have
revealed only closed-pore conformations (9-12). Single channel electrophysiology data
has indicated that there seem to be five closed and up to four open components, based
on dwell times (102), but how those components relate to structural changes is
unknown. Using cryo-EM microscopy, Tajima, et al. were able to identify a class of
conformations that, based on the extracellular domains, they suggested to be the
active conformation of the NMDA receptor (11). However, these data comprised only
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17% of the identified particles, and their reconstruction was unable to resolve the
TMD to any high degree. Nevertheless, the low resolution map that can be seen
indicates that there are some large, backbone-changing conformational movements in
the TMD present during channel activation. The mapping of the conformational
changes of the NMDA receptor TMD is the subject of Chapter 6.

Carboxyl-Terminal Domain
The carboxyl-terminal domain is the least structurally clarified domain of the
NMDA receptor. Believed to be intrinsically disordered, the CTD is not essential to
function and has been removed from all the constructs used for high-resolution
structural determination (9-12). Nevertheless, the CTD plays a number of roles,
including membrane targeting, stabilization, and degradation (1). It contains a
number of phosphorylation sites that control use-dependent desensitization (103) and
trafficking (104, 105). Moreover, the CTD undergoes palmitoylation (106), and also,
through interaction with calcium/calmodulin, mediates calcium-dependent
inactivation (107-109).
Perhaps most interestingly, as well as controversially, the CTD is also
responsible for metabotropic function of the NMDA receptor (110, 111). While NMDA
receptors, as well as calcium, are necessary for induction of both LTP and LTD,
blocking of NMDA receptor ion flux by either a pore blocker or by a GluN1
competitive antagonist does not prevent LTD induction (112). This finding was both
refuted (113) and confirmed (114), by independent groups, highlighting the controversy
in the area. Given the length of the NMDA receptor CTD, there would be precedent
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for a non-ionotropic mechanism mediated by intracellular conformational changes,
and indeed FLIM-FRET experiments with GluN1 subunits tagged with GFP and
mCherry show conformational changes even when ion flux is blocked (115). To date,
the CTD has been the least studied domain of the NMDA receptor, but these studies
show that there is still a wealth of information to be discovered about its functions.

15

Chapter 3: Single-molecule Förster Resonance Energy Transfer
This chapter is based in part upon Dolino, D. M., S. S. Ramaswamy, and V.
Jayaraman. 2014. Luminescence Resonance Energy Transfer to Study Conformational
Changes in Membrane Proteins Expressed in Mammalian Cells. e51895. The full article
may be found at http://www.jove.com/video/51895/luminescence-resonance-energytransfer-to-study-conformational.
The preceding two chapters have highlighted the importance of NMDA
receptor function and have illustrated some of the gaps present in the literature
regarding the structure-function relationships that govern NMDA receptor activity.
The high-resolution structural information of the outermost three domains has
provided great insight into the endpoints of conformational activity, but information
about the movements and dynamics of the receptor in between those endpoints is
lacking. In order to address this gap, we have used single-molecule Förster Resonance
Energy Transfer as a means to directly assess conformational changes during changes
in NMDA receptor function.
Förster Resonance Energy Transfer, or FRET, is a technique that can be used as
a molecular ruler to measure distances and distance changes between donor and
acceptor fluorophores within the range of 10-100 Å (116, 117). In this range, if the
emission spectrum of the directly-excited, donor fluorophore overlaps with the
absorption spectrum of the acceptor fluorophore (Figure 2), resonance energy
transfer can occur where the donor transfers its energy non-radiatively to the
acceptor. The efficiency of this transfer is highly distance-dependent and can be
described by the following equation:
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𝐸=

𝑅0 6
𝑅6 + 𝑅0 6

(1)

where R is the distance between the two fluorophores, E is the efficiency of transfer,
and R0, defined below, is the Förster radius for the fluorophore pair, i.e. the distance at
which efficiency of transfer is half-maximal. From this equation, one can see that
efficiency is related to the magnitude of the distance raised to the sixth power, and it
is this sixth power dependence that allows for FRET measurements to be exquisitely
sensitive to even small distance changes when near the R0 of the FRET pair.
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Figure 2. Excitation and Emission spectra of a typical FRET fluorophore pair
Excitation spectra are shown in dashed lines, and emission spectra are shown
in solid lines. Donor spectra are shown in blue, and acceptor spectra are shown in red.
FRET can occur when the emission spectrum of the donor overlaps with the excitation
spectrum of the acceptor (highlighted), and results in a highly distance-dependent
non-radiative energy transfer. The area of overlap is known as the overlap integral,
and is an important factor in characterizing the R0 for a fluorophore pair.
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FRET efficiency E is defined as the ratio of the rate of energy transfer, kFRET,
divided by the total rate of decay, kFRET + Σkother for the donor fluorophore:
𝐸≡

𝑘𝐹𝑅𝐸𝑇
𝑘𝐹𝑅𝐸𝑇 + ∑ 𝑘𝑜𝑡ℎ𝑒𝑟

(2)

Taking the relationship of lifetime being the inverse of the rate, this equation can be
rewritten:
𝐸=

τ𝐷 − τ𝐷𝐴
τ𝐷

(3)

where τD is the lifetime of the donor fluorophore alone (representative of the rate of
decay for all other processes), and τDA is the lifetime of the donor when participating
in energy transfer with the acceptor (representative of the sum of kFRET + Σkother)(118).
When measuring donor lifetime, care must be taken to account for background
donor-only lifetimes in cases where there is incomplete labeling or photobleaching of
the acceptor. To circumvent this complication, LRET experiments using lanthanide
cations acting as donor fluorophores measure the lifetime of sensitized acceptor
emission, i.e. acceptor emission resulting from excitation via donor energy transfer
rather than direct acceptor excitation. Because the lifetime of the organic acceptor
fluorophore is so short compared to the lifetime of even a FRETting lanthanide (nsec
vs μsec), the acceptor lifetime can be considered instantaneous and thus be used as a
good reporter of FRET donor lifetime (119).
Fluorophore lifetime measurements of single molecules can also be achieved
using time-correlated single photon counting (TCSPC) technology or by frequency
modulation; however, given the expense of the equipment needed for these
techniques, intensity-based FRET measurements can be taken, integrating the
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fluorescence over the course of 10 - 100 msec. In this case, a proximity ratio, PR, can
be taken as the ratio of acceptor fluorescence to total fluorescence:
I𝐴
𝐼𝐷 −1
𝑃𝑅 =
= (1 + )
I𝐷 + 𝐼𝐴
𝐼𝐴

(4)

where IA is the intensity of acceptor emission and ID is the intensity of donor emission.
To relate this proximity ratio to actual FRET efficiency, background signal,
spectral cross-talk, and direct acceptor excitation must be subtracted from the raw
signal, such that
𝐼𝐷 = 𝑆𝐷 − 〈𝐵𝐷 〉 − 𝛽(𝐼𝐴 + 𝑓𝑑𝑖𝑟 )
𝐼𝐴 = 𝑆𝐴 − 〈𝐵𝐴 〉 − 𝛼𝐼𝐷 − 𝑓𝑑𝑖𝑟

(5)

where Si is the raw signal from either donor (D) or acceptor (A) prior to any
correction; <Bi> is the mean background signal, taken either between bursts or from
each spot after photobleaching; β is the spectral cross-talk parameter of acceptor
emission detected in the donor channel; α is the spectral cross-talk parameter of donor
emission detected in the acceptor channel, and fdir is direct excitation of the acceptor by
the donor laser. The spectral cross-talk parameters can be obtained by directly exciting
singly-labeled samples and taking the appropriate ratio of background-corrected signal;
whereas fdir is simply measured as the background-corrected acceptor signal upon
excitation with the donor laser.
Furthermore, the signal detected from a given quantity of excited molecules
will be dependent on the detection efficiency at that wavelength and the molecule’s
quantum yield, and so the differences in those values between the donor and acceptor
must be accounted for in accurate efficiency determination. These two factors are
combined into the single correction factor γ, where
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𝐼𝐷 −1
𝐸 = (1 + 𝛾 )
𝐼𝐴

(6)

And
𝛾=

𝜂𝐴 𝛷𝐴
𝜂𝐷 𝛷𝐷

(7)

with ηA and ηD being the detector efficiency of acceptor and donor emission,
respectively, and ΦA and ΦD being the quantum yield of the acceptor and donor
fluorophores, respectively. These values can be measured empirically, or γ can also be
measured as the magnitude of the ratio of the change in signal after acceptor
photobleaching (120) as a means to normalize the change in measured signal to the
same corrected emission:
∆𝐼
𝛾 = | 𝐴|
∆𝐼𝐷

(8)

where ΔIA is the change in measured acceptor signal after acceptor photobleaching,
and ΔID is the change in measured donor signal after acceptor photobleaching.
After calculating the FRET efficiency, the distance between the fluorophores
can then be calculated with equation 1, given the R0 value of the FRET pair. If the R0
value is unknown for the pair of fluorophores, it can be calculated via the following
equation:
1/6

8.785 × 105 × κ2 × ϕ𝐷 × 𝐽
𝑅0 = (
)
𝑛4

(9)

where, R0 is the Förster radius in angstroms, κ2 is the orientation factor between the
two dyes usually assumed to be 2/3, ϕD is the quantum yield of the donor, n is the
refractive index of the medium, and J is the spectral overlap integral between the
donor's emission spectrum and the acceptor's absorbance spectrum in M-1cm-1nm4
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(Figure 2). J is defined in equation 10
𝐽 = ∫ ̅̅̅
𝑓𝐷 (𝜆)𝜀𝐴 (𝜆)𝜆4 𝑑𝜆

(10)

where ̅̅̅
𝑓𝐷 is the donor emission spectrum normalized to an area of 1, ϵA is the molar
absorbance coefficient of the acceptor at the given wavelength in M-1cm-1, and λ is the
wavelength in nm (116-118).
The κ2 value given in equation 9 is the orientation factor. Fluorescence and
energy transfer, being dipole interactions, are dependent on the relative orientation of
those dipoles. If the dipoles are oriented in parallel, the orientation factor will be at its
maximum of 4. If the dipoles are orthogonal to each other, they will be at a minimum
value of 0. In practice, the long linkers attached to the fluorophore dyes allow for free
rotation of the dyes and an average κ2 value of experimental measurements to be close
to the theoretical average of 2/3 (121). An uncertainty of 10% in the R0 can be assumed
with confidence, while gathering anisotropy data directly can lower this uncertainty to
2.5% or lower (91). Keeping this in mind, by affixing FRET fluorophore pairs onto
proteins via site-directed labeling, single molecule and even ensemble FRET can be
used to make high-precision measurements of protein conformational changes and
structure (121, 122).
Isolation of single molecules for smFRET can be done in two main ways. In the
first, very dilute and highly pure FRET-labeled samples are simply dropped onto a
clean glass slide, with the labeled samples allowed to diffuse around. Using a confocal
microscope, the experimenter can focus onto a small, femtoliter-size confocal volume
in the middle of the sample solution. As labeled sample diffuses into and out of the
confocal volume, they will give off bursts of fluorescence emission that will then be
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detected as single molecule FRET data (91, 123). In the second method of isolation,
labeled samples are physically attached to microscope slides. These slides must be
extremely clean and passivated, typically using PEG, to prevent any non-specific
binding of proteins or other contaminants. To capture protein, the layer of PEG can be
doped with biotinylated PEG, which will then irreversibly bind streptavidin.
Biotinylated antibodies can then pull down proteins or other samples of interest (89,
90, 120).
Each method of single molecule isolation has its pros and cons. With diffusingFRET, the sample must be very pure—many contaminants fluoresce and thus it may
be difficult to distinguish contaminant signal from actual sample signal. Assuming
that the slide is clean and the antibodies specific, attached-FRET allows for the
washing away of contaminants, but the assumption of clean slides and specific
antibodies is not always a safe one. Attached-FRET allows for the tracking of single
molecules over a period of seconds, limited only by photobleaching times. DiffusingFRET can only capture FRET traces for as long as a molecule stays within the confocal
volume, though efforts have been made to capture proteins within lipid vesicles to
lengthen the dwell time. Finally, the confocal-based microscopy combined with timecorrelated single photon counting (TCSPC) measurements can allow for the capture of
fast dynamics, even faster than the up-to-80 MHz pulse rate of the laser (see Chapter
5), whereas the best cameras for TIRF-based attached FRET go to around 30 msec
resolution. Confocal microscopy and TCSPC data collection can also be used with
attached-FRET, but this comes at a cost of throughput (120, 123). Analysis of the
smFRET data is similar and will be discussed in the relevant chapters below.
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Chapter 4: Elucidating the Structural Mechanism of Partial Agonism of the
NMDA Receptor
This chapter is based upon research originally published in The Journal of
Biological Chemistry. Dolino, D. M., D. Cooper, S. Ramaswamy, H. Jaurich, C. F.
Landes, and V. Jayaraman. Structural Dynamics of the Glycine-binding Domain of the
N-Methyl-D-Aspartate Receptor. Journal of Biological Chemistry. 2015; 290: 797-804.
© the American Society for Biochemistry and Molecular Biology.
As discussed in Chapter 2, one of the central questions concerning the NMDA
receptor prior to the work of this dissertation was how agonist binding leads to
channel activation. Insight into iGluR structure and function had previously been
dominated by studies on the AMPA receptor and has shown that the LBD folds into a
clamshell-like shape that can close upon its ligands, inducing conformational changes
that result in channel opening. Crystal structures of the AMPA receptor LBD showed
that the extent of this cleft closure correlates with the efficacy of the ligand, with weak
agonists inducing partial closure, and full agonists inducing full cleft closure and full
channel activation (95-97, 124-126). Such a relationship between LBD cleft closure and
ion channel activation provided an elegant means of explaining the link between
conformational changes at the LBD and opening of the channel pore (127). Moreover,
smFRET experiments as well as NMR experiments on the AMPA receptor showed that,
in addition to the inherent ability of a ligand to induce cleft closure, the dynamics of
the LBD also play an important role in dictating activation (128-133).
With the NMDA receptor, while at the glutamate-binding site of the NMDA
receptor the extent of cleft closure at the LBD does appear to correlate to activation,
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such a graded cleft closure was not observed, either by crystal structures or by
ensemble LRET measurements, for the glycine-binding domain (4, 6, 92, 134). Based
on the crystal structures of the isolated LBDs, it has been suggested that the glycinebinding GluN1 subunit could follow a mechanism of conformational selection wherein
the apo state probes both the closed- and open-cleft conformations. In this
mechanism, agonist efficacy is governed by the stabilization of the closed
conformation rather than the formation of intermediate states as was noted with the
AMPA receptor LBD. Consistent with this hypothesis and with the distinction from
AMPA receptors, theoretical investigations of the apo state of GluN1 revealed a
narrowly distributed closed-cleft population in addition to an expected broad opencleft population (135). While the theoretical studies shed light on the apo- and
glycine-bound states of the NMDA receptor, experimental evidence for the
mechanism of partial agonism at the LBD still remained largely unknown.
To address this question, we used smFRET to allow us to examine the
conformational landscape that the isolated glycine-binding GluN1 LBD (GluN1 S1S2)
probes in the presence of full agonists, partial agonists, or an antagonist. Additionally,
in order to specifically label the protein at desired sites, we incorporated the unnatural
amino acid p-acetyl-L-phenylalanine into the protein (136). The unique ketone group
of p-acetyl-L-phenylalanine can be coupled to hydrazide-conjugated fluorescent dyes
for the smFRET studies. Although smFRET on glutamate receptors has been done
before through the labeling of cysteine residues (132, 133), this new procedure allows
us to investigate the protein without concern of labeling or mutating out native
cysteine residues. We found that there is significant overlap between the different
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liganded states with the antagonist-bound protein samples exhibiting both the closedand open-cleft conformations, similar to what has been predicted with the molecular
dynamics simulations (135). Interestingly, we also found that the partial agonistbound proteins show greater rigidity in its population distribution, which was
different from what has previously been observed in the AMPA receptors (133).

Results
Cysteine labeling versus unnatural amino acid labeling
Previous protocols to study single molecule dynamics typically make use of
cysteine residues to enable site-specific labeling (132, 133). An important first step for
such approaches is to remove endogenous cysteines that may be undesirably labeled.
In the GluN1 LBD there is one non-disulfide-bonded cysteine at position 459 (Figure
3). The C459S mutant S1S2 protein could not be expressed well in Escherichia coli.
Further, smFRET investigations of wild-type protein labeled with thiol-reactive dyes
shows signal at the donor emission frequency but not at the acceptor frequency (FRET
signal) relative to the blank slide studied under the same conditions (Figure 4a and
Figure 4b). This result indicates that the single cysteine is accessible under these
labeling conditions, while the disulfide bonded cysteines are not labeled. This is
further confirmed by the double cysteine mutant at positions S507 and T701 which
shows signal in both the donor and acceptor frequencies (Figure 4c).
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Figure 3. Crystal structure of the GluN1 ligand-binding domain
Sites 507 and 701 were chosen to probe the dynamics of the GluN1 LBD and are
shown here in stick form with AcF side chains. Native cysteines involved in disulfide
bridges are shown in magenta, with the free cysteine shown in yellow.
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Figure 4. Labeling of wild-type proteins and mutant protein
Blue and red images show the donor and the acceptor channel response,
respectively, for the same areas. A,D, Blank slides without any protein bound. B, Purified
wild-type protein labeled with 1:1 ratio of maleimide derivatives of Alexa 555 and Alexa
647 showing labeling of the C459. C, Purified protein with cysteines at positions 507 and
701, labeled with 1:1 ratio of maleimide derivatives of Alexa 555 and Alexa 647. E, Purified
wild-type protein labeled with 1:1 ratio of hydrazide derivatives of Alexa 555 and Alexa
647. F, Purified protein with AcF inserted at positions 507 and 701 labeled with 1:1 ratio of
hydrazide derivatives of Alexa 555 and Alexa 647.
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These considerations made it difficult to use cysteines for analyzing dynamic
data. To address this issue, we introduced the unnatural amino acid p-acetyl-Lphenylalanine (AcF) by mutating to an amber stop codon at site 507 in Domain 1 and
at site 701 in Domain 2 (Figure 3, Figure 5).

a

b

Figure 5. Unnatural amino acids for use with single molecule FRET
A, The unnatural amino acid used for these experiments was p-acetyl-Lphenylalanine (AcF). B, Overview of the reaction between the AcF side chain and the
hydrazide functional group. The ketone of AcF reacts with the hydrazide to form a
covalent hydrazone bond.

In contrast to the experiments with the thiol reactive fluorophores, the wildtype protein shows no signal even after overnight treatment with ketone-reactive dyes,
similar to the blank control (Figure 4d and Figure 4e), indicating that none of the
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natural amino acids are reactive to the ketone-reactive dyes. Additionally, the mutant
protein with AcF at positions 507 and 701 showed signal at both the donor and
acceptor frequencies showing that the dyes specifically label only the introduced AcF
(Figure 4f).

smFRET investigations of the GluN1 LBD with full agonists, with partial agonists, and
with antagonist
The GluN1 LBD was examined by smFRET in the presence of the full agonists
glycine and D-serine, the partial agonists L-alanine and 1-amino-1-cyclobutane
carboxylic acid (ACBC), and the antagonist 5,7-dichlorokynurenic acid (DCKA)
(Figure 6a-e). Donor and acceptor photon counts of excited proteins were measured
with millisecond resolution, collected into 10 ms bins for efficiency determination,
denoised using wavelet decomposition, and then plotted as separate histograms as
described previously (132, 133, 137).
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Figure 6. Denoised smFRET histograms showing the population distribution of
the GluN1 ligand-binding domain in various liganded states
Distribution of FRET values for the GluN1 LBD when bound to A, full agonist
glycine (85 molecules), B, full agonist D-serine (28 molecules), C, partial agonist L-alanine
(38 molecules), D, partial agonist ACBC (166 molecules), and E, antagonist DCKA (121
molecules).
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The smFRET histograms of the different ligand-bound states show FRET
efficiencies that range from 1 to 0.5 with a peak at 0.95. The FRET efficiency of 0.95
corresponds to a distance of 31 Å. This distance is similar to the 34 Å measured in the
crystal structure between the Cα of residue 507 and the Cα of residue 701, which is in
good agreement with the FRET data, given that the FRET distances are measured
between the fluorophores (4). A smaller peak appears around an efficiency of 0.72,
corresponding to a distance of 44 Å. This distance is comparable to the 41 Å distance
measured in the apo crystal structure. The fact that the different liganded states show
occupancy covering this entire range suggests that the protein probes both the
“closed’ and “open” cleft conformational states (135). The small fraction of occupancies
(summing to less than 10%) at efficiencies below 0.6 reflect hyperextended open-cleft
conformations that are most likely accessible due to the isolated nature of the LBD
and the absence of the membrane and amino-terminal domain.
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a

b

Figure 7. Comparison of the smFRET histograms
A, Comparison of the smFRET histogram for the LBD when bound to antagonist
DCKA (dark red) or with the full agonist glycine (green). B, Comparison of the smFRET
histograms for the GluN1 LBD when bound to full agonist glycine (green) or partial
agonist ACBC (orange).
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A shift toward lower efficiency states is seen when comparing the smFRET data
of full agonists to that of the antagonist DCKA (Figure 7a). Specifically, the DCKAbound form of the protein has a reduced number of occurrences at 0.96 or higher
efficiencies and a much larger fraction at 0.88 efficiency (37 Å) relative to the forms
bound to the full agonists glycine or D-serine. This trend to lower efficiencies is again
consistent with the crystal structures which show an open-cleft conformation for the
antagonist-bound protein (4). Interestingly, the common 0.95 peak underlies the
significant overlap in the smFRET data between the antagonist- and agonist-bound
forms of the GluN1 LBD. This data is consistent with theoretical calculations of the
apo state of the glycine-binding domains of the NMDA receptor, which show that the
protein probes both open- and closed-cleft conformations (135). The smFRET data,
however, do not show a clear appearance of a new, distinct population between the
two liganded forms, but only a shift in the population from a more closed-cleft
conformation in the full-agonist-bound state to a more open-cleft conformation in the
antagonist-bound state (Figure 7a).
The histograms for the GluN1 LBD when bound to the partial agonists ACBC or
L-alanine

also show a peak FRET efficiency at 0.95, which corresponds to a distance of

31 Å (Figure 6). This distance is in agreement with the distance of 32 Å measured in
the crystal structure of the ACBC-bound LBD between the Cα of residue 507 and the
Cα of residue 701 (6). The LBD in complex with L-alanine has not been crystallized.
The peak efficiency seen in the partial agonist-bound forms of the LBD is similar to
that found in the glycine-bound state of the protein, again consistent with the crystal
structures that show a similar closed-cleft conformation with all activating agonists.
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Crucially, both of the partial agonist-bound forms of the LBD probe smaller ranges of
conformations and are thus more rigid compared to the glycine-bound state of the
protein (Figure 7b). Moreover, between the two partial agonists, the ACBC-bound
form seems even more rigid than L-alanine, in line with ACBC being a less effective
partial agonist than the latter (6, 138). This finding seems to be in direct contrast to
the AMPA receptor, which shows a broader range of closed-cleft conformations when
comparing partial agonist-bound forms to full agonist-bound forms (133).

Discussion
Here, we have shown that the mechanisms of agonist action at GluN1 are
different from those of AMPA receptors due to the fact that the protein tends to
occupy a much narrower spread of states in the full agonist-, partial agonist-, and
antagonist-bound forms. The differences are more evident in the partial agonist- and
antagonist-bound forms, as a decrease in agonism for the AMPA receptors is reflected
by a large increase in the spread of cleft-closure states. In the GluN1 LBD the shifts are
much less dramatic. The decreased spread in the cleft-closure states probed by the
GluN1 LBD could be one of the reasons that no significant changes were observed in
the extent of cleft closure in the crystal structures between the partial agonist- and full
agonist-bound forms.
While the two receptors show differences in terms of dynamics of the LBD
between the various ligand-bound states, there is still a linear dependence for the
GluN1 LBD between activation and the fraction of protein exhibiting FRET efficiencies
greater than 0.96 (Figure 8). This result is similar to what was observed in the AMPA
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receptors where a similar linear dependence between the fraction of receptors in highefficiency states versus activation was observed (133). Thus, while the dynamics are
different for the two subtypes, the underlying mechanism wherein the extent of cleft
closure controls extent of receptor activation still seems to be preserved.

Figure 8. Cleft closure versus activation
Plot of the fraction of the LBD of the GluN1 subunit that exhibits FRET efficiencies
higher than 0.96 versus normalized mean currents (6, 138) obtained with the
corresponding ligands in full-length GluN1/GluN2B receptors.
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Apart from the characterization of the GluN1 LBD dynamics, the studies
performed here show that unnatural amino acids can be used as a means to label
proteins for smFRET. The ability to introduce amino acids with a unique ketone
functional group allows for labeling of proteins with high specificity. Avoiding the
conventional thiol-maleimide chemistry allows investigators to disregard any
problems with cysteines native to the protein, as well as alleviating worries about the
formation of disulfide bridges with the introduced cysteines. The commercial
availability of p-acetyl-L-phenylalanine, as well as the commercial availability of
various hydrazide-conjugated fluorescent labels, allows for the use of a wide variety of
FRET fluorophore pairs with various distance ranges.
In conclusion, we have demonstrated here the use of ketone-containing
unnatural amino acids for smFRET measurements to analyze the conformational
dynamics of the GluN1 LBD in complex with the full agonists glycine and D-serine, the
partial agonists L-alanine and ACBC, and the antagonist DCKA. The use of unnatural
amino acids allows for the specific labeling of proteins and has the flexibility of being
used with a wide variety of fluorophores. The smFRET histograms of the GluN1 LBD
show a common high-efficiency peak, corresponding to a closed-cleft conformation
accessible to all examined liganded forms of the protein. These data are consistent
with previous theoretical results where the closed conformation was seen in both apoand glycine-bound forms of GluN1. Additionally, the difference in efficacy appears to
be correlated with the ability of the ligand to select specifically for the closed
conformation.

37

Chapter 5: Probing NMDA Receptor Dynamics with Submillisecond Resolution
This chapter is based upon research originally published in The Journal of
Biological Chemistry. Dolino, D. M., S. Rezaei Adariani, S. A. Shaikh, V. Jayaraman,
and H. Sanabria. Conformational Selection and Submillisecond Dynamics of the
Ligand-binding Domain of the N-Methyl-D-aspartate Receptor. Journal of Biological
Chemistry. 2016; 291: 16175-16185. © the American Society for Biochemistry and
Molecular Biology.
The previous chapter dealt with a first look at understanding the mechanism of
partial agonism. To do so we used attached smFRET with cutting edge unnatural
amino acid technology to provide the first experimental evidence of a partial agonistdependent change in the conformational equilibrium of the GluN1 LBD; however, the
time resolution for those experiments was limited to 10 ms. With the kinetic
movements of the GluN1 LBD occurring faster than this resolution (139) and the lack
of a clear conformational model, more robust experimental methods were needed to
clarify this mechanism of partial agonism.
To probe the conformational landscape of the GluN1 LBD at faster time scales
than previously studied, we used smFRET and multi-parameter fluorescence detection
(MFD) to obtain a complete experimental investigation of the dynamics and
conformational equilibrium of the GluN1 LBD. MFD experiments can be used as
another method of obtaining smFRET data, but in contrast to obtaining the intensitybased FRET efficiency of individual molecules over a period of seconds, MFD
experiments simultaneously measure a number of fluorescence parameters, including
intensity, lifetime, and anisotropy of molecules, as they diffuse one at a time through a
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small confocal volume. The use of time-correlated single-photon counting (TCSPC)
allows for the exploration of dynamic motions in a broad range of time scales, down to
picoseconds (123), making this method particularly well suited for observing the
mechanism of partial agonism of the GluN1 LBD. The isolated GluN1 LBD was purified,
and site-directed labeling with fluorescent dyes was performed to probe the distance
across the LBD cleft (Figure 9) (90). The results presented here show that the GluN1
LBD exhibits a common closed cleft, active arrangement among a variety of agonists,
with partial agonists showing less stability of the closed conformation and more
dynamic conversions to the open conformations. Moreover, we find among the FRET
states one conformation, which resembles within 2.8 Å the published crystallographic
structure for the glycine-bound configuration, and another state that differs only by
1.6 Å from the DCKA-bound structure (4).
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Figure 9. Experimental smFRET design and construct validation
A, Schematic representation of the glycine-bound (PDB code 1PB7, orange) and
DCKA-bound (PDB code 1PBQ, blue) conformations of the GluN1 ligand-binding
domain of the NMDA receptor. The accessible volume (AV) simulations were
calculated to determine the available space that the fluorescent marker will occupy
with the donor (Alexa 488) at Ser-507 and acceptor (Alexa 647) at Thr-701. The green
“AV-cloud” represents all the locations the donor dye can access, and the green and
red spheres represent the mean positions of the dyes for donor and acceptor,
respectively, for each structure. The distance between the mean position at each
conformation is Rmp = 44.8 and 51.3 Å for glycine and DCKA bound, respectively. Their
corresponding expected mean FRET efficiency distances are 〈RDA〉E = 48.7 and 54.2 Å.
B and C, whole cell electrophysiological recordings were performed to confirm
retained functionality and efficacy of ligands with GluN1 S507C/T701C. B, a
representative trace shows the reduced efficacy of the two partial agonists, ACBC and
L-alanine,

relative to the two full agonists, glycine and D-serine, as well as the

antagonist DCKA. C, group data showing the relative efficacy of each ligand with
respect to glycine. Glycine: 100%, D-serine: 94 ± 1%, L-alanine: 84 ± 6%, ACBC: 25 ±
4%, DCKA: 0.3 ± 0.1%.
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Results
smFRET experimental design and construct validation
The GluN1 LBD was mutated to cysteines at Ser-507 and Thr-701 (full-length
sequence) on opposite sides of the cleft as has previously been described (89, 90), and
then labeled using the FRET pair Alexa 488 and Alexa 647, with an R0 of 52 Å. Based
on crystallographic studies of the glycine-bound (PDB code 1PB7, orange) and DCKAbound (PDB code 1PBQ, blue) conformations of the LBD, we performed in silico
labeling and determined the expected mean FRET efficiency distance 〈RDA〉E = 48.7
and 54.2 Å, for both structures, respectively (Figure 9a). With this construct, one
should be able to observe the clamshell closure due to the binding of different ligands.
To verify that these mutations (GluN1 S507C/T701C) do not abolish the
functionality and efficacy of ligands in the full receptor, we obtained whole cell
electrophysiological recordings (Figure 9b). Ligand efficacy was determined by
normalizing to the maximum amplitude in presence of the full agonist glycine. As
expected, D-serine, also a full agonist, has similar efficacy to glycine, followed by Lalanine and ACBC. The last two are considered partial agonists (Figure 9c).

Construction of smFRET histograms
For single molecule experiments, we used pulsed interleaved excitation (PIE) of
donor and acceptor fluorophores to excite the doubly labeled LBD. The emitted
fluorescence photons were collected to measure various FRET efficiency indicators of
single molecules of the LBD when in complex with different ligands (glycine, 1 mM; Dserine, 1 mM; L-alanine, 15 mM; ACBC, 10 mM; or DCKA 100 μM). FRET efficiency was
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measured simultaneously through both intensity measurements and donor lifetime
measurements in the presence of the acceptor (Figure 10). The resulting singlemolecule events or burst histograms are presented in a multidimensional
representation, where each event was preselected according to a 1:1 donor to acceptor
stoichiometry. The cleaned FRET signal is shown as contours on two-dimensional
histograms and as filled histograms over the one-dimensional 〈τD(A)〉f and FD/FA
projections. The green sigmoidal line over the two-dimensional histogram represents
the static FRET line (Equation 13 (see Appendix), Table 1), which is the theoretical
relationship between the two FRET indicators: the donor fluorescence average lifetime
〈τD(A)〉f and the ratio of donor-to-acceptor fluorescence (FD/FA). Populations that lie on
the line indicate FRET states that are “static” (123), i.e. populations with dynamic
interconversion rates that are slower than the burst duration.
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Figure 10. MFD histograms of labeled GluN1 LBD with multiple ligands
Two-dimensional single molecule FRET histograms using burst analysis of
FD/FA distribution versus fluorescence averaged lifetime (〈τD(A)〉f). The green line is the
static FRET line, which describes the relationship between FD/FA and fluorescence
averaged lifetime (〈τD(A)〉f). The GluN1 LBD of the NMDA receptor was diluted to
picomolar concentrations in the present of various ligands. A, 0.1 mM DCKA; B, 1 mM
glycine; C, 1 mM D-serine; D, 15 mM L-alanine; and E, 10 mM ACBC. The following
parameters were used: 〈BG〉 Gly = 0.93, 〈BR〉 Gly = 0.51, 〈BG〉 D-Ser = 0.93, 〈BR〉 D-Ser =
0.532, 〈BG〉 L-Ala = 0.842, 〈BR〉 L-Ala = 0.502, 〈BG〉 ACBC = 0.955, 〈BR〉 ACBC = 0.518,
〈BG〉 DCKA = 0.94 〈BR〉 DCKA = 0.522, β = 0.02 (fraction of direct excitation of
acceptor with donor excitation laser), α = 0.017, and gG/gR = 3.7.
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Table 1. FRET Lines
Equation 13 was used for each different experiment.
Sample

Static FRET Line

Gly

(0.7732/0.4240)/((3.8660/((-0.0405*τD(A)f3)+
(0.2914*τD(A)f2)+0.4891*τD(A)f -0.0422))-1)

D-Ser

(0.8286/0.4290)/((4.1430/((-0.0348*τD(A)f3)+
(0.2676*τD(A)f2)+0.4977*τD(A)f -0.0443))-1)

L-Ala

(0.8426/0.4130)/((4.2130/((-0.0335*τD(A)f3)+
(0.2622*τD(A)f2)+0.4998*τD(A)f -0.0448))-1)

ACBC

(0.7990/0.3810)/((3.9950/((-0.0377*τD(A)f3)+
(0.2799*τD(A)f2)+0.4932*τD(A)f -0.0432))-1)

DCKA

(0.8498/0.3960)/((4.2490/((-0.0329*τD(A)f3)+
(0.2594*τD(A)f2)+0.5008*τD(A)f -0.0451))-1)

These MFD histograms show clear differences in the conformational
landscapes probed by the GluN1 LBD in complex with various ligands. As expected,
with the antagonist DCKA, mostly medium to low FRET states are explored, with a
longer donor fluorescence lifetime and a larger donor-to-acceptor fluorescence ratio
(FD/FA= 3.3) (Figure 10a). This is consistent with the stabilization of an open cleft
conformation. When in complex to the full agonist glycine, the FRET states shift
toward higher FRET efficiencies, indicated by lower donor fluorescence lifetimes and
smaller donor to acceptor fluorescence ratios (Figure 10b). This is also consistent
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with the stabilization of the closed cleft conformation. A second full agonist, D-serine,
shows a similar trend (Figure 10c), although not as pronounced. To assess the LBD
conformational space and dynamics across a variety of activation states we examined
two partial agonists (L-alanine and ACBC). Between the two, the more effective partial
agonist L-alanine (Figure 10d) resembled more the two full agonists, and the less
effective partial agonist ACBC (Figure 10e) resembled more the antagonist histogram,
similarly to the whole cell recordings (Figure 9b). Of note, the histograms for the two
partial agonists seemed to spread across a wider variety of conformational states,
though these states must be to some extent static because they lie along the green
FRET line. Altogether, it is then evident that none of the ligands trap a single state of
the LBD, but rather ligand binding redistributes the population of the conformational
states consistent with the mechanism of conformational selection.

Probability Distribution Analysis reveals three distinct conformations
To quantitatively analyze the conformational space and dynamic effects
induced by ligand binding, we used probability distribution analysis (PDA) (140, 141).
We used various models to fit the one-dimensional fluorescence ratio histograms with
multiple time windows (Δt = 5, 2, and 0.5 ms). In addition, we use PDA to identify the
mean FRET efficiency distance (〈RD(A)〉E) between the donor and acceptor for each
limiting state. For each conformational state, we use Gaussian distributions that
represent the interdye donor-acceptor distance distributions. In PDA analysis, the
width (hwDA) of each distribution is given by acceptor photophysics (142). To identify
the model that best represents the experimental data, we carry out a systematic
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approach of identifying the minimum number of shot-noise limited states (no
Gaussian distribution of states). We reached a reasonable convergence with three
different FRET states based on visual inspection of the weighted residuals (w. res) and
the figure of merit χ2. To improve the fit, we added the contribution of the donor-only
population due to acceptor bleaching. Although we have burst selection with 1:1
donor-to-acceptor stoichiometry, the presence of donor-only population indicates
that a significant fraction of the acceptor is photobleached within the duration of the
time window. To identify and remove this artifact further, we used the ratio of the
prompt signal corresponding to the TCSPC channels of donor excitation (Sprompt) and
total uncorrected signal of donor and acceptor emission over all TCSPC channels
(STotal) (donor and acceptor excitation in PIE experiments) (Figure 11a). It is worth
mentioning that the stoichiometry parameter is corrected for quantum yield and
detection efficiencies; however, the raw detected signal (S) does not require additional
corrections. Therefore, this selection serves as an additional identification of events
that smear toward the donor only population due to photobleaching. We ruled out the
possibility of a very low FRET state due to very long interdye distances because after
the Sprompt/STotal (Figure 11a) selection there were no remaining bursts with high
enough FD/FA ratio and 1:1 stoichiometry.
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Figure 11. Photobleaching and description of FD/FA histograms as modeled by
PDA
A, Removing all acceptor photobleaching due to incorrect signal of prompt
channel over all data (0.5 < SPrompt/STotal < 0.8). B, Experimental and PDA-modeled
FD/FA histogram distributions at Δt = 5 ms for the LBD in the presence of glycine.
Three limiting states were depicted as Gaussian distributions, each with a different
color (high FRET, orange, medium FRET, navy, and low FRET, wine). The mean FD/FA
value of each distribution is shown as a vertical line with the same color code. Each
line correlates to the experimentally determined interdye distance per state or 〈RDA〉E.
One dynamic transition is shown as Gaussian (dashed dark yellow line).

47

After identifying the minimum number of FRET-related conformations, we
increased the level of complexity in the fitting model. For example, we know that
intensity-based FRET parameters are determined by fluctuations on the integrated
acquisition time. PDA is particularly susceptible for capturing the blinking behavior of
dyes, which produces additional broadening of the distribution beyond the shot noise
limit. This behavior has been well characterized (142). It is known that broadening is
caused mostly due to acceptor blinking and it follows a monotonic relationship with
respect to the interdye separation distance (142). Thus, each FRET-related
conformational state will have its own distribution of distances with a particular width
(hwDA) and mean interdye distance 〈RDA〉E. Note that Rmp and 〈RDA〉E represent
different distances (see accessible volume in Appendix). Benchmark studies (121, 143)
have shown that 6% of the interdye distance 〈RDA〉E is a typical effective width per
state. Thus, we fixed the distribution width to 6% of each 〈RDA〉E. Broadening beyond
this limit would be considered to emerge from dynamic processes.
To exemplify this representation, we show in Figure 11b the experimental and
PDA modeled FD/FA histogram distributions at Δt = 5 ms for the LBD in presence of
glycine. Here, we identify three limiting states depicted as Gaussian distributions,
each with different color (high FRET orange, medium FRET navy, and low FRET wine).
The mean FD/FA value of each distribution is shown as a vertical line with the same
color code. Each line correlates to the experimentally determined interdye distance
per state or 〈RDA〉E. In addition to three limiting states, one dynamic transition, also
shown as Gaussian (dark yellow), is added to statistically improve the fitting quality.
For example, in this case χ2 decreases from 4.7 to 1.15, when dynamics is included at
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Δt= 5 ms. Weighted residuals (w. res.) are shown on top layer for visual representation
of the goodness of the fit. In a simplified representation it is possible to only show the
model distribution as compared with the experimental histogram and the vertical lines
for representing the mean FD/FA value per state. Hereafter, this simplified
representation will be used.

Time window analysis reveals submillisecond dynamics
To study if there were any dynamic processes involved in the submillisecond to
millisecond time scale between states, the experimental FD/FA distributions were
globally fit using three time windows (Δt = 5, 2, and 0.5 ms). If all states were static
within the time window, the static model would roughly fit all time windows equally
well and the probability distribution would not change. This was the case for the LBD
bound to DCKA and ACBC, suggesting slow kinetics with those ligands (Figure 12 for
DCKA and ACBC). The figure of merit χ2 and the modeled FD/FA distribution are
shown in red when the states are treated as static and it is shown in green when the
model includes a dynamic transition. If during the selected time window, a molecule
switches multiple times between states, the fluorescence bursts of the interconverting
molecules will show different degrees of mixing between states; thus changing the
probability distribution. This is only true if the dynamic interconversion occurs at
time scales that are smaller or comparable to the selected time window. The need for a
dynamic state was noticeable for the glycine, D-serine, and L-alanine bound states
(Figure 12), whereas for DCKA and ACBC χ2 increases with the addition of a dynamic
state.
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Figure 12. Time window and PDA comparison of FD/FA histograms of the LBD
with the various ligands
Time window (Δt) analysis for 0.5, 2, and 5 ms (A–C, respectively). The same
FD/FA correction parameters are used as described in the legend to Figure 10. The
dynamic PDA model consists of three static FRET states (HF, MF, and LF) plus a single
two-state kinetic transition between HF and MF. Fractions are renormalized to
consider only FRET populations. We observe that glycine has a faster relaxation time
compared with L-alanine as glycine equilibrates within the selected time windows. A
similar result is seen with D-serine. Splitting of populations occur in the case of
L-alanine.

Relaxation times are shown in Table 2. Vertical lines correspond to the

mean FRET efficiency distance of the three limiting states (HF, orange; MF, blue; and
LF, magenta; Table 2). Donor only or acceptor photobleaching region has a dark gray
background. Tables 2, 3, 6, and 7 summarize the results from PDA.
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The larger differences comparing multiple time windows in the distribution for
L -alanine

are indicative of intermediate kinetics in the millisecond to submillisecond

time scales. It is obvious in this case that there is a split of states with an increase in
population of the higher FRET states. Faster kinetics equilibrates the distribution at
shorter time windows as seen in the case of glycine because there is no split of states.
However, there is evidence of population redistribution toward higher FRET
efficiencies or lower FD/FA ratios. Therefore, the static model use of three FRET states
is no longer valid. To include the dynamic component we tested the addition of a
single two-state transition between any FRET states. Remember that the mean FD/FA
value of each state is shown as a vertical line with the same color code and the
relationship to distance can be readily determined (Tables 2 and 3).

Table 2. 〈RDA〉E determined by PDA analysis

Sample

High-FRET
(HF) [Å]

Medium-FRET
(MF) [Å]

Low-FRET
(LF) [Å]

All

33.9

45.8

55.8
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Table 3. FD/FA ratio for each given mean FRET distance
Sample

High-FRET (HF)

Medium-FRET (MF)

Low-FRET states (LF)

Gly

0.14

0.86

2.8

D-Ser

0.15

0.9

2.9

L-Ala

0.16

1.0

3.1

ACBC

0.16

1.0

3.2

DCKA

0.16

1. 0

3.2

FD/FA = (Quantum Yield Donor/Quantum Yield Acceptor)* (RDA/R0)6

(R0=52 Å)

We observed that the single two-state kinetic state (HF ⇌ MF) was needed to
significantly improve our figure of merit (χ2) across time windows for the LBD bound
to the full agonists and to the partial agonist L-alanine. In summary, for all cases, we
identified three FRET states with the following interdye distances: the high FRET (HF)
(〈RDA〉E = 33.9 Å), medium FRET (MF) (〈RDA〉E = 45.8 Å), and low FRET states (LF)
(〈RDA〉E = 55.8 Å) (Table 2).
These distances were determined with the assumption that κ2 = 2/3. To
validate this assumption, the κ2 distribution for these conditions was determined
using the wobble in a cone model (Figure 13). For this, we assume that the residual
anisotropies can be approximated in the worst case scenario to the average steady
state anisotropy per burst, or 〈rss〉 ≅ r∞, for D-only (donor), A (acceptor), and A(D)
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(the sensitized by FRET emission of acceptor) from single molecule experiments
(Table 4). As the observed κ2 value will be dynamically averaged among all possible
values within this distribution, we then use the mean value, <κ2>, to calculate distance
and observe that the maximum error introduced by this assumption is 2.5% (Table 5),
thus, validating our assumption.

Table 4. Average steady state anisotropy (rss) per burst for the dyes on the
ligand-binding domain at the conditions
rss
D-only
A
D(A)
A(D)

Gly
0.15
0.36
0.18
0.03

D-Ser

L-Ala

0.13
0.06
0.18
0.04

0.1
0.04
0.13
0.03

ACBC
0.15
0.06
0.18
0.04

DCKA
0.11
0.07
0.15
0.05

Figure 13. κ2 distribution for LBD bound to: A, DCKA; B, Gly; C, D-Ser; D, L-Ala;
and E, ACBC
The line for κ2 = 2/3 is shown in red for each distribution. Mean κ2 is shown in
blue.
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Table 5. Mean κ2 and estimated error (

〈𝜿𝟐 〉

𝑹𝑫𝑨

〈𝜿𝟐 =𝟐/𝟑〉

𝑹𝑫𝑨

assumption of κ2 = 2/3

%) on distances by using the

Sample

κ2

%
Error

Gly

0.636

2.2

D-Ser

0.631

2.5

L-Ala

0.637

1.8

ACBC

0.634

2.5

DCKA

0.641

2.0

The addition of a two-state kinetic transition (HF ⇌ MF) occurring in the
submillisecond time scales indicate that D-serine exerted the fastest exchange
dynamics (tR = 3.5 μs; Table 6), followed by glycine (tR= 7.6 μs) and L-alanine
exhibited slower kinetics with tR = 50 μs (Table 6).

Table 6. Fastest relaxation time observed with PDA
Sample

tR [ms]

Gly

0.0076

D-Ser

0.0035

L-Ala

0.050
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The dynamic analysis overall suggests that the full agonists glycine and Dserine have rapid dynamic motions specifically associated with the LBD rapidly
fluctuating between the MF and HF states, whereas the partial agonist L-alanine has
slower dynamics with occasional visits to the HF state. ACBC and DCKA appear static
in the millisecond time scale as shown in Figure 14. ACBC has a slightly higher
fraction in the HF state relative to DCKA. Note that static populations represent slow
exchange at time scales longer than the burst duration, or trapped states. These data,
when correlated to the activation profile, suggest that the visits of the LBD to the HF
states are critical for the agonist to activate the channel. This is also consistent with
the previously published single channel recordings where it has been shown that
partial agonists tend to have longer closed times, which would be consistent with the
slower kinetics observed for the partial agonists (139). In addition, when combining
the contribution of the static populations and the two-state kinetics between the HF
and MF states, we observe that L-alanine is found more often exchanging over these
two states more than the two full agonists glycine and D-serine and thus spends less
time in the active state. The summary of all population analysis is presented in Table
7.
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Figure 14. Redistribution of population fractions
A, The population of the static contribution of FRET states. B, A single twostate kinetic state (HF ⇌ MF) was used to model the additional dynamics observed.
The bar plot shows the distribution of populations of the HF and MF states. The
derived distances for high FRET, medium FRET, and low FRET states are
〈RDA〉E = 33.9 Å (HF), 〈RDA〉E = 45.8 Å (MF), and 〈RDA〉E = 55.8 Å (LF) and are shown by
orange, blue, and purple, respectively (Table 2). Dynamics fractions were obtained by
globally fitting 3 time windows (Δt = 0.5, 2.0, and 5 ms). DCKA and ACBC do not have
dynamic contributions. C, separation of static and dynamic populations that
contribute to the overall scheme. L-Alanine is found more often exchanging at
submillisecond time scales.
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Table 7. Overall fractions of PDA analysis including the donor only (bleached
fraction)

Sample

High-FRET
(HF)

Medium-FRET
(MF)

Low-FRET
(LF)

Donor only/
Acceptor
bleaching

Gly

59.4

14.4

5.5

20.7

D-Ser

9.7

37

11.1

42.2

L-Ala

13.6

22.8

0.0

63.6

ACBD

3.40

18

30.2

48.4

DCKA

2.0

21.4

40.8

35.8

Discussion
To investigate the mechanism of partial agonism in the GluN1 subunit of the
NMDA receptor, we have measured the cleft opening and closing motion of the LBD
of the NMDA receptor in the presence of the full agonists glycine and D-serine, the
partial agonists L-alanine and ACBC, and the antagonist DCKA. The presence of the
ligands redistributed the state populations, indicative of the conformational selection
and preferred state. Even in the presence of ligands the LBD showed dynamic
sampling of at least three different FRET conformations that could be separated with
our FRET measurements. To quantify the dynamics, we used PDA and time window
analysis to provide population analysis and relaxation times of exchange rates between
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the MF and HF populations. These results show that the LBD when bound to an
antagonist spends much of its time in the open-cleft conformation leading to a closed
channel. Although there is a significant fraction of the MF state shared in all ligands, it
seems that this conformation does not directly lead to activation of the channel.
When comparing the measured FRET distance with the expected distances computed
from the AV modeling using the crystallographic structure (PDB code 1PB7) we obtain
the experimentally determined MF distances as 〈RDA〉E = 45.8 Å, whereas the AV
expected distance is 〈RDA〉E = 48.7 Å. Thus, we can clearly see that the MF population
resembles within 2.8 Å the crystallographic structure in the presence of ligand. For the
DCKA state (PDB code 1PBQ) we experimentally determined a LF distance 〈RDA〉E =
55.8 Å compared with the expected distance of 〈RDA〉E=54.2 Å from AV simulations.
Again, excellent agreement is found with a 1.6 Å difference.
Moreover, in Figure 14 one could also observe that, although there are
significant changes between various partial agonists and the full agonists, faster
kinetics are observed for the full-agonist bound LBD. The relaxation time (tR) of the
glycine-bound LBD is almost an order of magnitude faster than the tR observed when
the LBD is bound to the partial agonist L-alanine. These findings are in good
agreement with single-channel recordings that showed longer closed times when
bound to partial agonists (139), and faster kinetics is observed for the receptor in the
presence of glycine than in the presence of L-alanine. Additionally, the primary three
closed states seen in single channel recordings appear to correlate with the three
states observed in the smFRET data here, with the HF state being the one more likely
leading to channel activation. Thus, the data presented here nicely joins the
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experimental structural data seen in x-ray crystallography with the experimental
functional data of single-channel electrophysiological recordings to create a unified
explanation of the mechanism of partial agonism at the GluN1 LBD.
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Chapter 6: Investigation of the Gating Movements of the NMDA Receptor
The previous two chapters discussed the conformational change that occur at
the ligand-binding domain that eventually result in channel opening; however, what,
if any, are the conformational movements that actually occur at the channel segment
itself? For over 30 years, single ion channel recordings have suggested that channel
proteins exist in multiple closed and open conformations. As electrophysiological
techniques have advanced, the set of ion channel states and our ability to distinguish
them have grown to encompass a multitude of long-lived and short-lived shut states
(144, 145). Despite the advances in single channel recording approaches, the ability to
distinguish transitions between shut states is limited by the fact that these shut states
are all electrophysiologically silent. The multiplicity of closed states is not restricted
only to single-channel data but has also become increasingly prominent with the rise
of cryo-electron microscopy. States previously assumed to be homogenous are
increasingly revealed to reflect a variety of underlying conformations (11, 146).
Single molecule FRET of surface-immobilized molecules is uniquely suited to
probing of the conformational heterogeneity associated with these predicted closed
and open states. NMDA receptors are an ideal candidate for such smFRET studies as
they have a rich history of single channel studies with several sound reaction
mechanisms involving discrete shut states across multiple time scales (139, 147, 148).
Further, there exist a number of full-length structures of NMDA receptors in apo
(unliganded), antagonist-bound, and allosteric modulator-bound states (9-12, 149),
and NMDA receptor channel gating is relatively slow and thus approaches the
temporal resolution of smFRET (120, 150).
61

Though the available structural information provides excellent insight into the
structure-function relationships within the extracellular domains of the NMDA
receptor; the transmembrane segments which comprise the ion channel pore itself are
less well-resolved, especially in the open-channel configuration. Consequently,
structure-function analysis of this region has been more challenging. Past functional
studies probing the transmembrane segments have focused primarily on
conformational changes between the apo and open states (59, 62), and implicate the
disordered linker region connecting the LBD and transmembrane segments as being
crucial for coupling. Still unclear though, is whether desensitization or allosteric
inhibition themselves induce any conformational rearrangements in the
transmembrane segments, or how such conformational changes might be driven by
the binding of extracellular agonists and allosteric ligands. Furthermore, most
functional studies using macroscopic recordings have, out of necessity, treated the
apo, desensitized, and inhibited states as discrete conformations, while single channel
analysis reveals each of these classes to be a collection of interconverting states (94,
139, 151). To explore these issues, we have performed smFRET on full-length
GluN1/GluN2A NMDA receptors labeled at residue 554 of the GluN1 linker region
proximal to the first transmembrane segment, and examined this site in resting (apo),
agonist-bound (open and desensitized), and zinc-bound (allosterically inhibited)
conditions. This method revealed conformational changes in the transmembrane
domain that are associated with channel opening. In addition, we also observed that
the receptor occupies multiple closed states that have different kinetic and structural
properties under apo, desensitized, and inhibited conditions. These data provide the
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first experimental evidence for the range of transmembrane conformations that the
receptor adopts and moreover shed light on the structural landscape associated with
the functional data. The data also provide the first evidence for differences in the
closed channel conformations adopted by apo, agonist-bound, and allosterically
inhibited receptors.

Results and Discussion
Functional characterization of the smFRET construct.
To investigate the conformational changes of the NMDA receptor
transmembrane domain in various functional states using smFRET, we introduced a
fluorophore-labeling site using the mutation F554C in GluN1. Residue 554, found
within the linker region connecting the LBD to the first transmembrane segment of
the transmembrane domain, was chosen for its accessibility to labeling as well as for
minimal expected perturbation of receptor function (Figure 15a). To minimize nonspecific labelling by donor and acceptor fluorophores (Alexa 555 maleimide and Alexa
647 maleimide, respectively) the accessible cysteines Cys15 and Cys22 in GluN1 and
Cys231, Cys399, and Cys460 in GluN2A were mutated to serines, and the resulting
background constructs are referred to hereafter as GluN1* and GluN2A*(71-73, 92).
Electrophysiological characterization of labeled GluN1*F554C/GluN2A* receptors
show that activation, desensitization, and inhibition (Figure 15b) are all preserved.
Specifically, responses to a 1-ms pulse of 1 mM glutamate with constant glycine in
outside-out patches deactivated with a weighted time constant of 43 ± 6 ms (n = 11,
Figure 15b, left). In response to a 5-second long 1 mM glutamate application, the
63

smFRET construct showed rapid activation (10-90% rise-time, 7 ± 1 ms, n = 11) and
desensitized to 20. ± 3% of the peak response with a weighted time constant of 110 ±
20 ms (n = 11, Figure 15b, left). Furthermore, the channel block by both MK-801 (1
µM, 93 ± 2% steady-state inhibition, n = 8, Figure 15b, middle) and inhibition by Zn2+
(10 µM, 83 ± 5% steady-state-inhibition, n = 5, Figure 15b, right) were intact in whole
cell recordings.
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Figure 15. TMD smFRET constructs and characterization
A, GluN1*F554C/GluN2A* NMDA receptors were labeled with donor and
acceptor fluorophores at site 554 of GluN1, proximal to the first transmembrane
segment of GluN1 (mean fluorophore positions shown as green or red hard spheres
surrounded by a fluorophore cloud). B, Representative electrophysiological responses
from the smFRET construct showing deactivation (gray) and desensitization (black)
(left), inhibition by 1 µM MK-801 (middle), and by 10 µM Zn2+ (right, recorded at +50
mV).
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smFRET identified distinct and stable states.
For smFRET experiments, GluN1*F554C/GluN2A* receptors were
recombinantly expressed in HEK cells, labelled with donor and acceptor fluorophores,
and purified using in situ immunopurification on prepared coverslips (152) (see
Appendix). As with prior experiments using soluble iGluR domains (89, 90, 132, 133),
sample scanning confocal microscopy showed clearly resolved single spots on these
coverslips which were not present when unmutated GluN1*/GluN2A* was used
(Figure 16). Single molecule FRET trajectories were collected from these full-length
labelled GluN1*F554C/GluN2A* receptors under various liganded conditions, and the
resulting ensemble-averaged denoised FRET efficiency histograms are shown in
Figure 17. The raw trajectories were denoised using wavelet decomposition and
specific states were identified using Step Transition and State Identification (STaSI)
analysis (89, 153, 154) (Table 8, Figure 17 insets). STaSI analysis was performed
independently per ligand dataset, and the discrete states identified through STaSI
were supported by fitting the ensemble observed FRET efficiencies to a sum of
Gaussians corresponding to those states (89)(Figure 18).
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Figure 16. Attached-FRET of full-length NMDA receptors shows specific
pulldown
Control slides showing minimal fluorescent protein when labeling cells
expressing background NMDA receptors (top panel) and with FRETting single
molecules with the F554C construct.
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Figure 17. Denoised smFRET histograms of the NMDA receptor
smFRET data of the NMDA receptor were obtained under varying ligand
conditions, denoised via wavelet decomposition (154, 155), and used to generate
smFRET efficiency histograms. STaSI analysis was performed to reveal the underlying
conformational states. Peaks corresponding to each STaSI state are labeled with the
state efficiency. The STaSI states represented by Gaussian noise fitting to the observed
FRET histogram can be seen in Figure 18. Shown in an inset above each histogram is a
representative observed efficiency trace, the denoised trace (lighter shade), and the
STaSI fit (black). The different conditions studied were A, the apo, unliganded
receptor B, the agonist-bound (Glu-Gly) receptor C, the agonist-bound receptor in the
presence of the open-channel blocker MK-801, and D, the agonist-bound receptor
inhibited by the allosteric inhibitor zinc. The high-efficiency state seen in A indicates a
closed-channel conformation for an apo receptor not seen with the agonist-bound
receptor. The increased populations of the low efficiency states in C identify those
states as representing open-channel conformations. The reappearance of the highefficiency state in D implies that zinc modulation proceeds not simply by stabilizing
desensitized conformations, but by decoupling the cleft-closure of the agonist-binding
domain to conformational changes of the transmembrane segments.
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Table 8. Conformational states sampled by the NMDA receptor under various liganded conditions.
Conformational states were identified using Step Transition and State Identification analysis (89, 153). Distances for the
states were calculated with an R0 of 51 Å. There is a high degree of similarity among the states seen, as may be expected of a
conformational selection model sampling the same states at different populations.
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Assignment
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distance
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Glutamate-Glycine/MK-801

States
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FRET
distance
(Å)

States

Percent
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FRET
distance
(Å)

0.46 ±
0.02

7.1
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0.02
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49 ± 1

Open

Glutamate-Glycine/Zn2+

States

Percent
Occurrence

FRET
distance
(Å)

Open

0.58 ±
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0.60 ±
0.02

4.3

48 ± 1

Closed

0.74 ±
0.02

14.6

43 ± 1

0.70 ±
0.02

18.4

44 ± 1
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0.82 ±
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Figure 18. Observed smFRET histograms of the NMDA receptor
Ensemble histograms of the observed data are shown. The STaSI states are
shown here, represented as Gaussian noise, whose sum fits well with the observed
histogram. A, Apo receptor B, agonist-bound receptor C, agonist-bound receptor with
MK-801, D, zinc-inhibited receptor.
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The conformational landscape associated with open and closed channel states.
To evaluate the difference between closed and open channels, we compared
the histogram obtained in apo conditions with the histogram obtained under
saturating concentrations of agonist (1 mM glutamate and 1 mM glycine, Figure 19a
and b). The histogram of the apo NMDA receptor (Figure 17a) shows five discrete
states, with the predominant state (50.3% occupancy) at a FRET efficiency of 0.92 ±
0.02. The glutamate-glycine bound histogram (Figure 17b) also shows five states;
however, the receptor occupancy distribution is shifted toward the lower efficiency
states. In particular, the glutamate-glycine states with FRET efficiencies of 0.46 ± 0.02
and the 0.60 ± 0.02 states are rarely observed with the apo receptor (1.6% occupancy
at 0.58 ± 0.02 with no observed population corresponding to the 0.46 ± 0.02 state).
This shift toward lower efficiencies when glutamate-glycine are bound suggests that
channel opening is accompanied by a widening of the top of the transmembrane
domain. Given that unliganded, apo receptors show no spontaneous channel opening
in the absence of ligands, we assigned the FRET efficiency states at 0.46 ± 0.02 and
0.60 ± 0.02 to open channel conformations with the rest of the states corresponding
to closed conformations. To validate this assignment, we employed MK-801, an openchannel blocker that binds to and stabilizes the channel’s open conformation (156).
Inclusion of MK-801 along with glutamate and glycine should increase the relative
proportion of the open-channel conformational states and reduce the relative
proportion of the closed-channel conformational states. Consistent with this, the
ensemble smFRET histograms show a notable shift toward lower FRET efficiencies
(Figure 17c, Figure 19c-f, Table 8). STaSI analysis of the data revealed six states with
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MK-801, five of which align with the states for the glutamate-glycine bound receptor
(Table 8). Of these five states, the 0.48 ± 0.02 and the 0.62 ± 0.02 states seen with
MK-801 have higher relative occupancies compared to their counterparts in the
glutamate-glycine-bound receptor. MK-801 also stabilizes an additional state at 0.56 ±
0.02, which is unexplored or highly transient in its absence. This smFRET-based
assignment of states as functionally open is reinforced further by the agreement
between the smFRET ‘open’ state occupancy (16.3% in the liganded condition, Table
8) and the residual steady-state current after desensitization (20 ± 3% of peak
response, n = 11) in our electrophysiological measurements of the smFRET construct
(Figure 15b).
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Figure 19. Difference histograms clarify the changing conformational landscape
of the NMDA receptor as it shifts between inactive and active conditions
Parent denoised FRET efficiency distribution histograms were paired and
subtracted from one another to generate difference histograms. The positive/negative
value of the difference histogram signifies higher/lower relative abundance of one
condition as compared to the other. Shown are the parent and difference histograms
for A,B, apo vs. glutamate-glycine-bound receptor, C,D, apo vs. glutamate-glycine with
MK-801, E,F, glutamate-glycine vs. glutamate-glycine with MK-801, G,H, glutamateglycine vs. glutamate-glycine with zinc, and I,J, and Apo vs. glutamate-glycine with
zinc.
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Consequently, the three higher-efficiency states explored by the glutamateglycine-bound receptor (0.70 ± 0.02, 0.82 ± 0.02, 0.90 ± 0.02) can be assigned to
closed-channel conformations. Their distances of 44.3 ± 0.7 Å, 39.6 ± 0.9 Å, and 35 ± 1
Å, respectively, between the fluorophores are in good agreement with the X-ray and
EM-based structures of the closed-channel receptor, which show a Cα-Cα distance of
30 Å. Additionally, the distance change of 17 ± 1 Å between the most closed state (0.90
± 0.02) and the more open state (0.46 ± 0.02 efficiency, 52.4 ± 0.7 Å) is similar to the
22 Å change at the M3 helix between the closed-channel EM structure and the lowresolution EM structure thought to represent the open receptor(11).
The apo receptor additionally explores an additional high-efficiency state at
0.98 ± 0.02 (27 ± 5 Å) (Figure 17a, Table 8). This closed state has no corresponding
equivalent in the glutamate-glycine bound receptor or with the glutamate-glycine
receptor with MK-801, but rather this state is unique to the apo, unliganded state.
Because cleft closure of the LBD leads to channel opening at the transmembrane
domain via the linker between them (59), this high-efficiency state of the apo receptor
most likely arises from a lack of tension at that linker due to the absence of ligand in
the agonist-binding cleft. That this state is not the predominantly populated closed
state is reflective of the ability of LBD to dynamically sample closed-cleft
conformations in apo and even antagonist-bound conditions (90, 91, 135).

Comparison of desensitized and inhibited NMDA Receptor.
To obtain a fuller understanding of the gating motions of the NMDA receptor,
we also examined the accessible conformational states of the transmembrane domain
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in the presence of the divalent cation zinc, which acts as an allosteric inhibitor (71, 73,
151). Like other allosteric inhibitors, zinc binds to the amino-terminal domain of
GluN2 subunits, inducing cleft closure and a reduction in channel activity (11, 12, 71,
73, 149, 151, 157), though the precise nature of the conformational changes that occur
at the transmembrane segments upon zinc binding are still unknown. Figure 17d
shows the ensemble histogram of the denoised FRET data, which are primarily shifted
toward more closed states as compared to the state of the agonist-bound receptor
alone (Figure 19g and h). However, in addition to stabilizing the agonist-bound
closed states, another high-efficiency, more closed state is observed at 0.96 ± 0.02
(Figure 17d, Table 8), which is structurally distinct from the closed states probed
with glutamate and glycine. The efficiency of this more closed state in the presence of
zinc is similar to the 0.98 ± 0.02 state observed in the apo form of the receptor
(Figure 17a, Table 8), and in fact their histograms are remarkably similar (Figure 19i
and j). Thus, rather than simply shifting the conformational equilibrium of the
glutamate-glycine-bound receptor toward its closed states, as has been previously
suggested, the binding of zinc results in the more compact “apo-like” state of the
receptor’s transmembrane segments. These data suggest that allosteric inhibition by
zinc may occur through a mechanism in which amino-terminal domain cleft closure
allows for the decoupling of the extracellular domains from the transmembrane
segments, permitting the transmembrane segments to move to more closed
conformations.
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Dynamics of the NMDA receptor.
Beyond providing the conformational landscape that the NMDA receptor
probes, our smFRET data also provide insight into the dynamics of the receptor. The
smFRET traces under apo conditions were relatively static (Figure 17a, inset),
whereas the traces of the liganded receptor were much more dynamic (Figure 17b,
inset). To quantify the differences in transition frequency, we first examined the
average number of transitions occurring in time-windows of varying length for each
condition (Figure 20a), which confirm that the apo condition indeed exhibited a
much lower average number of transitions than receptors in other conditions.
Interestingly, the allosterically inhibited zinc-bound form of the receptor exhibits a
comparable number of transitions to the other liganded conditions, despite being
electrically less active and with an overall histogram reminiscent of the apo condition.
These transitions of the inhibited receptor, however, are primarily between the
highest-efficiency closed states, as discussed later. Such behavior is reminiscent of
single-channel recordings, which display long-lived shut states interspersed with
clusters of electrical activity (158). As a second measure of conformational fluctuation,
the cumulative probability plot of the coefficient of variation (CV) of each single
molecule trajectory is shown in Figure 20b. Static, stable traces exhibit low CV,
whereas dynamic traces exhibit a higher CV. As with the average transitions over time,
apo receptors show much less variation and the cumulative probability rises quickly at
a low CV value. In contrast, a much larger portion of the agonist-bound and MK-801bound traces show higher variation and so the rise is slower. Zinc-inhibited receptors,
on the other hand, though they undergo as many transitions as do the other liganded
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receptors (Figure 20a), show a steeper rise, intermediate between the glutamateglycine and the apo receptors. As described below, this behavior is consistent with the
zinc-bound receptors exhibiting transitions between a smaller range of states,
fluctuating mainly among the closed states, and rarely visiting open states.
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Figure 20. Dynamics of the NMDA receptor show differences in transitional
behavior under different ligand conditions
A, The average number of transitions seen per time window show that
unliganded apo receptors exhibit notably fewer transitions than any of the liganded
receptors. B, The cumulative probability plot of the coefficient of variation shows that
the apo receptor is the most unvarying of the receptors, with few transitions. Zincinhibited receptors show a higher level of variation, while the uninhibited glutamateglycine bound receptors show a high degree of variation. Figure 21 shows that this
relationship is not due to effects of the length of the individual traces. C,
Autocorrelation of the single molecule data fit to three-term exponential decay. The
thickness of the lines represents the fitting errors (zoomed in for visibility in inset).
The lifetimes show that uninhibited glutamate-glycine bound receptors have a higher
amplitude of the longest-lived component, as well as a longer weighted average
lifetime, as compared to the apo and inhibited receptors, indicating increased
transitions for uninhibited receptors and increased rigidity for the apo and inhibited
receptors.
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Having various lengths of the smFRET trajectories does not affect the CVligand condition relationship.
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As a final measure to examine the transmembrane domain rigidity, the
autocorrelation of each of the smFRET trajectories was calculated to generate an
average autocorrelation curve for each set of ligand conditions. The average
autocorrelation curves were fit to a three-term exponential decay, and the exponential
fits yielded three different fluctuation timescales for each receptor condition: short
(τ1), intermediate (τ2), and long (τ3) (Figure 20c and Table 9). Short autocorrelation
decay times indicate a more rigid nature of the molecules, whereas longer decay times
indicate the opposite (132). The process associated with the longest timescale (τ3) can
be attributed to conformational transitions or protein fluctuation events (159). As
expected, apo and inhibited receptors have smaller amplitudes for this timescale,
whereas agonist-bound NMDA receptors have the greatest amplitude for this
timescale. Furthermore, the trend in overall weighted average fluctuation timescales
indicates that the liganded receptors exhibit a longer overall decay compared to the
apo and inhibited receptors, again reflecting the greater stability of electrically
inactive receptors under these conditions.
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Table 9. Autocorrelation data under the various ligated conditions.
The average autocorrelation decay of the single molecule FRET data was fit to a
three-term exponential decay, resulting in short, intermediate and long timescale
decays for each condition. The longest timescale decay was most prevalent for
uninhibited liganded receptors, and was least prevalent for the apo and inhibited
receptor. These data indicate that uninhibited receptors exhibit the most transitions,
indicative of a shallow energy barrier into channel opening, whereas apo and inhibited
receptors are the most rigid, with a high energy barrier preventing transitions into
channel opening.

Ligand

Short
timescale
τ (ms)

Amplitude
(%)

1

Intermediate
timescale
τ (ms)

Amplitude
(%)

Long
timescale
τ (ms)

Amplitude
(%)

Weighted
average
lifetime τ
(ms)

3

2

Apo

8±1

46.4 ± 0.7

170 ± 10

30 ± 1

860 ± 60

23 ± 2

250 ± 20

Glu-Gly

9±3

37 ± 1

82 ± 6

24.3 ± 0.9

650 ± 10

38.9 ± 0.7

275 ± 6

9±1

309 ± 2

65 ± 5

34 ± 2

740 ± 20

35.9 ± 0.6

292 ± 9

13 ± 1

39 ± 1
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34 ± 2

640 ± 40

26 ± 2

220 ± 20

Glu-Gly/
MK-801
Gly-Gly/
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Transitions among the open and closed states.
The smFRET trajectories further allow us to determine the transitions between
and among the closed and open states. Transition maps showing the relative number
of transitions from one state to the other are shown in Figure 22a-d. The data show
that transitions primarily occur between states of nearest FRET efficiency, whereas
transitions between non-adjacent states are less common. More importantly, the
transition maps for the receptors that show significant open-channel states (Figure
22b and 22c) suggest that channel opening occurs from a single closed state—a preopen state—which has the lowest FRET efficiency among the closed states. The two
other closed states, which have a higher FRET efficiency and thus more closed
transmembrane segments, do not show significant direct transitions into an open
channel state. Thus, a linear mechanism connecting the three closed states to the two
open states best describes the observed transition maps. Such a mechanism has a
striking similarity to the mechanism proposed based on single channel analysis which
show several closed states interconverting, but a single closed state transitioning to an
open state (151). Based on the present results, we can say that this ‘pre-open’ closed
state is structurally more open than the other closed states. Additionally, due to the
dynamics and the fact that both glutamate and glycine are present, the two other
closed states for the glutamate-glycine bound receptor can be assigned to the slower
closed states observed in single-channel recordings (151). Thus our data are able to
provide the first direct correlation between structural changes in the transmembrane
segments and functional changes previously reported using single-channel methods.
Furthermore, our results allow us to place these states along a plausible structural
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reaction coordinate corresponding to the functionally relevant distinction between
open and closed.
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Figure 22. Transition maps and free energy diagrams of the NMDA receptor
smFRET data
Examination of the individual single molecule traces show primarily transitions
between adjacent states, portrayed here in terms of the normalized number of
transitions for A, apo, B, glutamate-glycine bound, C, glutamate-glycine-bound with
MK-801, and D, glutamate-glycine-bound zinc-inhibited NMDA receptors. This
pattern indicates an ordered movement from closed to open conformations. E-H, Data
from these transition maps were used to generate free energy diagrams. These energy
diagrams explain the kinetic behavior we see in the receptor, with stabilization of the
open states for agonist-bound receptors and a high activation energy barrier for apo
receptors.
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Energetics of the NMDA receptor.
Based on the distribution of states (Figure 17a-d, Table 8) and the transition
maps (Figure 22a-d), the relative free energies of open and closed states along with
the relative free energy barriers for transitions between pairs of states were calculated
(160) (Figure 22e-h). These smFRET-derived data are again strikingly similar to the
free energy profiles proposed based on functional single-channel recordings (151),
though with our data showing a higher free energy for the open states of the agonistbound receptor, consistent with the desensitization profile of our smFRET construct
(Figure 15b). These energy profiles support our conclusion that the resting apo
receptor remains primarily in closed conformational states with a high activation
energy between states and thus fewer transitions. The zinc-inhibited receptor also
occupies primarily closed states, but the relative lower activation energy between the
states allows the zinc-inhibited receptor to exhibit more transitions than apo. The
ability of uninhibited agonist-bound receptors to activate the ion channel can be seen
by the lower activation energies between the pre-open closed states and the open
states, facilitating transitions between them.

Concluding remarks.
Here we have used single molecule FRET to examine the conformational
landscape of full-length intact NMDA receptors under various liganded conditions.
Our analysis revealed a multiplicity of FRET states in each dataset. The smFRET data
show similar efficiencies between different liganded conditions but with different
occupancies, consistent both with functional studies using single channel recordings
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and with the model of conformational selection at the level of the transmembrane
domain. Agonist binding lowers the energy barrier preventing the transitions of the
apo receptor, allowing the glutamate-glycine bound receptor to explore the open-state
conformations whilst destabilizing the tightest closed-state arrangement. Our studies
also show for the first time that the binding of the allosteric modulator zinc inhibits
the NMDA receptor by lowering the energy barrier of the glutamate-glycine bound
receptor leading into the apo-like tightest closed-state arrangement, essentially
decoupling the closed-cleft tension of the LBDs from the transmembrane segments.

89

Chapter 7: Conclusions and Future Directions
The work presented in this dissertation has made great strides toward
understanding the mechanisms of action of the NMDA receptor. Prior to this work,
the mechanism of partial agonism of the NMDA receptor glycine-binding domain was
unknown. Here, we combined cutting edge unnatural amino acid technology along
with single molecule FRET in order to reveal a variant of the graded cleft closure seen
with AMPA receptors (90). Due to the lower temporal resolution of the attachedFRET technique used, we pushed the boundary even further to achieve submillisecond
resolution of the dynamics of the glycine-binding domain (91). The data we obtained
are highly consistent with work from other groups, showing broad energy wells for the
apo LBD (135) and higher energy barriers relative to glycine for partial agonists (139).
Moreover, we were able to confirm a conformational selection-based mechanism of
the GluN1 LBD wherein the LBD can choose among three distinct conformational
states, with two of these states being consistent with crystal structures (4). Where our
work has stood out, though, is the revelation of the third state, hitherto unknown,
that we propose would lead directly into channel activation. Similarly, we have made
unprecedented advances in exploring the conformational dynamics of the
transmembrane domain of the NMDA receptor. Again, our data shows great
consistency with previous work (151), but the insight revealed by our studies has
allowed us to put forth a new mechanism by which NMDA receptors are allosterically
regulated.
This type of biophysical understanding of the NMDA receptor is of critical
importance. As discussed in Chapter 1, NMDA receptors play a whole host of roles
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within, and even outside of, the central nervous system. Physiological function is tied
to almost every cognitive process, and pathological dysfunction can be seen in a whole
host of disorders. In order to treat these disorders, a complete biophysical
understanding of these receptors is necessary for the development of better therapies
that can target aberrant receptors whilst minimally affecting those that are properly
functioning. Work from our lab has already made some ground toward this goal (161),
as has the work of others (56). With the knowledge gained from the studies presented
in this dissertation, such progress can be made again.

Future Directions
Despite the great progress made here, there is still much more work to do. The
NMDA receptor still hides many mysteries, and the abilities and techniques of our lab
are uniquely poised to address and answer some of the most critical among them.

Further investigations into the LBD
The works performed here on the LBD were performed on isolated domains;
however, recent technological advancements in the field and in our own lab have
made single molecule investigations of full-length proteins an achievable goal. As
discussed in their chapters, the flexibility seen in an isolated domain may not be
realized in the context of a full-length receptor, and so the dynamics observed for the
LBD may be quite different when approached in this manner. Indeed many LBD
interactions and properties depend on the presence of the rest of the protein, such as
desensitization, allosteric modulation, and intersubunit cooperativity (162). With our
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new ability to study the full-length receptor, the dynamics of the ligand-binding
domain must be revisited to see how the domain changes and reacts to a variety of
different conditions.

Dynamics of the Amino-Terminal Domain
The amino-terminal domain is unique among the iGluRs for its rich allosteric
potential, and the recent full-length structures have given insight into why, with its
extensive interface with the LBD (9, 10). Our work has already begun on this, with the
revelation of a zinc-mediated decoupling of the LBD to the TMD, but now a more
targeted look at the ATDs is essential. Does ifenprodil act in the same way? And how
does spermine potentiate—if the inhibitors decouple, what would be the opposite of
that? Moreover, even beyond allosteric ligands, the ATDs themselves impart different
properties on the receptor. A look at the dynamics of chimeric receptors would reveal
a great number of insights into how these domains exert their effects.

A closer look at the pore
The work presented here was a great leap forward, but now many smaller steps
need to be taken. Probing the TMD via the GluN2 subunits is a logical next step, as is
looking at the movements from the intracellular side. To really make the greatest
progress forward, however, two future goals should be strived for. The first is single
molecule patch-clamp FRET microscopy, and the second is single-molecule FRET
guided molecular dynamics. With single molecule patch-clamp FRET microscopy,
entailing the simultaneous acquisition of electrophysiology and single molecule FRET
92

data, the distinct conformational states that we saw in Chapter 6 can now mapped to
the different functional kinetic states. Temporal resolution of the attached-FRET
studies performed in that chapter have been the limiting factor, but the ability to
probe submillisecond ranges as described in Chapter 5 show that this is not an
insurmountable barrier. Certain technological advances and innovations may need to
be developed before such a union can be reliably called upon, the gain that will be
obtained from it will be immense.
Molecular dynamics and single-molecule FRET seem to me to be a natural
marriage of two techniques. Single molecule FRET can provide experimental
verification and guidance, while molecular dynamics will be able to provide atomiclevel insight into the motions of the protein. Such a marriage becomes especially with
proteins such as the NMDA receptor because, due to its sheer size, modeling of the
entire receptor would be a great computational burden. Single molecule FRET data
can thus provide constraints and an idea of the forces needed to direct a protein to
undergo a particular transition the experimenter wants to see. Conversely, the
necessity of labeling makes visualizing certain areas quite difficult via smFRET, e.g. the
inner lining of the pore. By combining our single molecule FRET data with steered
MD, I suspect a visualization of the permeation pathway, as well as the molecular
determinants of conductance, permeability, uncompetitive blocking, etc., are not far
off.
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The Carboxyl-Terminal Domain
The CTD is like the red-headed stepchild of the iGluR domains. It is the least
well-studied structurally, but despite that, or perhaps even because of it, the CTD in
recent years has come to be known to harbor many surprising and unexpected secrets.
CTD-mediated metabotropic activity of the NMDA receptor is an exciting, if
controversial, field that needs to be explored much more thoroughly. The intrinsically
disordered nature of the domain may provide problems for crystallographers and
cry0-EM microscopists, but it fits right into the wheelhouse of smFRET. Indeed, FRET
has already been used to explore these CTD motions (115), albeit with lower precision
due to the use of fluorescent proteins rather than dyes. Insights from single-molecule
studies can greatly clear up the mechanism of CTD-mediated non-ionotropic function.

Better technologies to study membrane proteins
Membrane proteins like the NMDA receptor make up about 30% of the
proteome and over 50% of drug targets, but structural and biophysical
characterization of these proteins are often hindered by that very membrane that
makes them so important. Current purification methods of membrane proteins
typically consist of ripping those proteins from the membrane and transferring them
into an unstable detergent micelle. Even if purified protein is subsequently
reconstituted into a lipid vesicle or a membrane scaffold protein (MSP) nanodisc,
there is often no guarantee that the lipids the protein is reconstituted in is
representative of the lipids in which the protein natively. Recently, styrene-maleic acid
copolymers have come into use as a means by which to solubilize membrane proteins.
94

Rather than simply removing the lipids from the protein, these SMA copolymers
extract nanodiscs from lipid bilayers, taking any embedded membrane proteins along
with them (163). The advantage of these “native nanodiscs” over MSP-based nanodiscs
would be that the native annular lipids that surround the protein would be intact.
Because the proteins have not been ripped away from lipids, proteins in these native
nanodiscs are more thermostable (164, 165) and retain function (164, 166). Not only
can individual proteins be purified, but complexes as well (167). Finally, a crystal
structure of an SMA-solubilized protein has recently been published, proving the
ability of SMA copolymers in the use structural work. The authors note no obvious
differences between the SMA-solubilized and traditional detergent-solubilized
structures, but take care to state that the use of SMA may obviate the necessity for
detergent screening and may facilitate working with more difficult membrane proteins
(168). In all, the advent of the SMA copolymer has made this is an exciting time for
membrane proteins and those who study them.

Final Thoughts
NMDA receptors are fascinating proteins that play pivotal roles in cognitive
function. The work presented in this dissertation has made great headway into
understanding the structure-function relationships of this protein, but much more
remains to be done. Fortunately, new technological advances and approaches are
coming out every day to help us delve into the mysteries that underlie, not only the
NMDA receptor, but life itself.
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Appendix: Materials and Methods
Parts of this section are based upon research originally published in The
Journal of Biological Chemistry. Dolino, D. M., D. Cooper, S. Ramaswamy, H. Jaurich,
C. F. Landes, and V. Jayaraman. Structural Dynamics of the Glycine-binding Domain
of the N-Methyl-D-Aspartate Receptor. Journal of Biological Chemistry. 2015; 290: 797804. © the American Society for Biochemistry and Molecular Biology. and Dolino, D.
M., S. Rezaei Adariani, S. A. Shaikh, V. Jayaraman, and H. Sanabria. Conformational
Selection and Submillisecond Dynamics of the Ligand-binding Domain of the NMethyl-D-aspartate Receptor. Journal of Biological Chemistry. 2016; 291: 16175-16185. ©
the American Society for Biochemistry and Molecular Biology.

Generation of site-directed isolated GluN1 LBD mutants
A pET22B vector encoding the rat GluN1 isolated LBD was provided by Eric
Gouaux (Oregon Health and Science University, OR) (4). Sites were chosen based on
accessibility and distance across the cleft. S507 and T701 (Figure 3) were mutated to
cysteines or to amber TAG codons using standard site-directed mutagenesis with Pfu
Turbo (Agilent). The original stop codon of this construct was also mutated from the
amber stop codon to encode an opal stop codon (UAA) to allow for successful
translation termination.

LBD protein expression
Mutant plasmid was co-transformed into Origami B (DE3) cells (Novagen)
along with the pEVOL plasmid containing the genes for the suppressor tRNA and
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aminoacyl-tRNA synthetase needed to incorporate p-acetyl-L-phenylalanine (pEVOL
plasmid was provided by Peter Schulz, Scripps Research Institute, CA) (136). 1-liter
liquid cultures were grown in LB broth, Miller (Fisher) supplemented with 50 μg/ml
ampicillin (Sigma), 15 μg/ml kanamycin (Fisher), 12.5 μg/ml tetracycline
(CalBioChem), and 50 μg/ml chloramphenicol (Acros) until they reached an OD600 of
0.8. Then, protein expression was induced by adding IPTG (Fisher) to a final
concentration of 0.5 mM. If needed, the unnatural amino acid machinery was
simultaneously induced by adding 0.02% arabinose (Sigma) and 1 mM AcF (RSP
Amino Acids). Induction was carried out at 20°C for 20-24 hours. The cultures were
then pelleted down, and the pellets were stored at -80°C until use.

LBD Protein purification
Pellets were thawed and lysed with a cell disruption vessel (Parr Instruments).
Then, cell debris was pelleted by spinning at 185,000 × g for 1 hr at 4°C. For large scale
purification with cysteine mutants, the GluN1 S1S2 in the supernatant was loaded onto
an immobilized metal affinity chromatography column that had been previously
charged with nickel sulfate (HiTrap HP, GE Healthcare) using fast protein liquid
chromatography (AKTA, GE Healthcare). Purified GluN1 S1S2 was then eluted using a
linear gradient of imidazole (Sigma). With smaller scale purification of the double
unnatural amino acid constructs, the supernatant was collected and purified by
binding with 1 ml of Ni-NTA agarose resin (Qiagen). Protein was then eluted with 200
mM imidazole (Sigma), concentrated down, and then brought to 500 μl in PBS, pH 7,
supplemented with 1 mM glycine (Fisher). Western blots of the purified mutant
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protein confirm expression of the full 35 kDa His-tagged LBD only upon induction of
the unnatural amino acid machinery, showing successful incorporation and utilization
of the unnatural amino acid (Figure 23a).
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Figure 23. Characterization of the GluN1 agonist-binding domain after
incorporation of p-acetyl-L-phenylalanine

A, Western blots showing lysates from 1L cultures probed with an antibody
against domain 2 of the GluN1 agonist-binding domain of wild-type protein and S507
and T701 double-mutant protein with or without induction of unnatural amino acid
machinery (UAA). Wild-type protein was diluted ten times to prevent oversaturation
of the blot. B, Isothermal titration calorimetry data from the GluN1 agonist-binding
domain having incorporated p-acetyl-L-phenylalanine. The Kd for binding MDL
105,519 is 7 ± 3 x 10-8 M, similar to the Kd determined previously with wild-type
agonist-binding domain (4).
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Labeling of LBD for FRET
Fluorescent dyes were added to the above protein sample. Alexa 555 and Alexa
647 (Invitrogen) were used as the donor and acceptor, respectively, for attached-FRET
experiments, whereas Alexa 488 was used as the donor for diffusing-FRET. For
cysteine labeling the maleimide derivatives were used. To label the unnatural amino
acids, we used ketone-reactive, hydrazide-conjugated fluorescent dyes (Figure 4).
Donor and acceptor dyes were pre-mixed, then added such that dye:protein molar
ratios were 1:1 for donor and 4:1 for acceptor, in order to minimize proteins labeled
with only donor fluorophores. Unnatural amino acid protein was labeled overnight at
4°C. The following day, excess dye was removed from the protein by dialysis in 2L of
PBS for 6 hours, changing the dialysis buffer every 2 hours. Glycine was added to the
dialysis buffer up to 1 mM for the glycine samples. With cysteine mutations, labeling
was performed for only 30 minutes before removing excess label by purifying the
protein onto a nickel affinity column (nickel-nitrilotriacetic acid-agarose, Qiagen).
Imidazole was used for elution and it was removed using a PD-10 desalting column
equilibrated with PBS buffer (GE Healthcare). For samples liganded to D-serine (Acros
Organics), L-alanine (Acros Organics), ACBC (Aldrich), or DCKA (abcam), the
appropriate ligand was added to the sample before and after each exchange if dialysis
was performed (1 mM, 15 mM, 10 mM and 1 mM, respectively, based on differential
affinities for each ligand). This type of ligand substitution was also performed for
glycine. No significant changes were noted and the glycine data was pooled for final
analysis. For attached smFRET experiments, 1 μg of biotin-conjugated anti-His epitope
antibody (Rockland) was added to a 500 μl sample.
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Isothermal calorimetry
The functionality of the GluN1 LBD protein with unnatural amino acids tagged
with fluorophores was determined using isothermal calorimetry (Figure 23b). For
these experiments the protein was extensively dialyzed to the apo state in buffer
containing 20 mM HEPES (pH 7), 150 mM NaCl, 1 mM EDTA, and 10% glycerol.
Calorimetric titrations were performed with VP-ITC (MicroCal) using 1 µM protein
with twenty 10 µL injections of 15 µM (E)-4,6-dichloro-3-(2-phenyl-2carboxyethenyl)indole-2-carboxylic acid (MDL 105,519) (Sigma) at 23°C. Data analysis
was performed using Origin (OriginLab).

Attached-smFRET LBD sample preparation (132)
For all single molecule measurements in this study, plasma-cleaned 22x22 mm
micro glass coverslips (VWR) were immersed in a VECTABOND-acetone solution (1%
w/v, Vector Laboratories, Burlingame, CA) for 5 minutes, rinsed with molecularbiology grade water, dried with nitrogen, and stored under vacuum to prevent
contamination. A silicon template was placed on the VECTABOND-functionalized
slide to allow filling of the future chamber area with PEG solution (5 kDa biotinterminated PEG (2.5% w/w in MB water, NOF Corporation) and sodium bicarbonate
(Sigma)) and the filled slide was allowed to dry in the dark for 4-6 hours. Excess PEG
was washed off with 10-12 ml MB water and, after nitrogen-drying the slide, a custom
HybriWell chamber (Grace Bio-Labs) fitted with an inlet and outlet port (press-fit
tubing connectors, Grace Bio-Labs) was arranged precisely over the PEGylated area.
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After filling the chamber with PBS buffer, a control image was taken to ensure a clean
sample, followed by insertion of 0.2 mg/ml streptavidin (Invitrogen) in PBS buffer.
Biotin-streptavidin binding was allowed to progress for 10 minutes. The protein of
interest, with the biotin-conjugated anti-His-antibody for streptavidin association,
was added to the chamber at an approximate concentration of 20 nM and incubated
for 20 min. Unbound protein was washed out by flushing the chamber with an excess
of PBS buffer.

Measurements of attached-FRET LBD data
The sample chamber was secured to a closed-loop x-y-z piezo stage (P-517.3CL;
Physik Instrumente) with 100 x 100 x 20 μm travel range and 1 nm specificity (SPM
1000, RHK Technology) to allow for precise movement of the sample area. In order to
extend the lifetimes of the fluorophores, an oxygen scavenging buffer solution of 33%
w/w β-D-(+)-glucose (Sigma), 1% w/w glucose oxidase, 0.1% v/v catalase (Sigma), 1
mM methyl viologen (Sigma), and 1 mM ascorbic acid (Sigma) in PBS was
continuously pumped through the chamber using a syringe-pump flow system at a
rate of 1 μl/min (169). Additionally, the above concentrations of the specific LBD
ligand, depending on the experimental conditions, was included in the buffer solution.
The custom-built confocal microscope (Zeiss Axiovert 200 M) described previously
was used for all smFRET measurements (137, 170). A 532 nm diode-pumped solid-state
laser (Coherent, Compass 315M-100 SL) focused through a FLUAR 100x 1.3 NA oil
immersion microscope objective lens (Carl Zeiss, GmbH) to a power density of 50
W/cm2 at the sample was used to excite the sample. Emitted light was collected back
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through the same objective and was passed through a notch filter (zet532nf, Chroma
Technology) and towards the detector box. The fluorescence emission light was
separated by a 640 nm high-pass dichroic mirror (Chroma 640 DCXR) and collected
by two corresponding avalanche photodiode detectors (SPCM AQR-15, Perkin Elmer)
set to 570 nm and 670 nm using band-pass filters (NHPF-532.0, Kaiser Optical and
ET585, Chroma Technology) for donor and acceptor signal collection. An area of 10x10
μm was raster scanned to locate individual molecules. After a single molecule was
chosen for observation, the stage was moved to focus the laser on the particular
molecule and then the donor and acceptor fluorescence signals were collected until
photobleaching of the fluorophores occurred.

Data analysis of attached-FRET LBD
A 1 ms time resolution was used to record the emission intensity trajectories
and then binned up to 10 ms frames during data processing to improve the signal-tonoise ratio. The data analysis was performed by an in house script using Matlab
(R2009b, Mathworks) which processed the signals via the wavelet denoising
technique (154, 155). The denoised signal was then used to calculate the FRET
efficiency at each time point, using Equation 6 (Chapter 3). (132, 133). From this FRET
efficiency, the distance was determined through Equation 1, the Förster equation. The
Förster radius is 51 Å for the Alexa 555-Alexa 647 fluorophore pair used for these
experiments. Error in FRET efficiencies was set at 0.03 based on measurements under
the same conditions performed with a rigid DNA double strand. The standard error of
the mean for the fraction of proteins with FRET efficiencies higher than 0.96 was
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calculated using the above error in FRET efficiency and determining the fractions at
the two extremes in error and by dividing by the square root of the number of
molecules studied for each ligand-bound state.
After processing the data, the traces were further filtered for single molecule
verification and excluded if they showed criteria of multistep bleaching or
exceptionally high background adapted from a normal distribution.

Electrophysiology for testing the LBD mutants
HEK-293T cells were transfected using jetPRIME® Polyplus with GluN1
S507C/T701C, wild-type GluN2A, and enhanced GFP at a microgram ratio of 1:3:1,
respectively, with 5 μg of total DNA/10 ml of medium. After a 10–12-h incubation with
transfection reagents, cells were plated at low density onto tissue culture dishes. 300
μM DL-APV and 30 μM DCKA were present in the medium during and after
transfection. Whole cell patch clamp recordings were performed 24–48 h after
transfection using borosilicate glass pipettes with 3–5 megohm resistance, coated with
dental wax, fire-polished, and filled with the following solution: 135 mM CsF, 33 mM
CsOH, 2 mM MgCl2, 1 mM CaCl2, 11 mM EGTA, and 10 mM HEPES, pH 7.4. The external
solution was: 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl2, 10 mM HEPES, pH 7.4. Solutions
were locally applied to isolated cells using a stepper motor system (SF-77B; Warner
Instruments) with triple barrel tubing. External solution alone was applied as a
control, and the cells were then pulsed with glutamate (1 mM) and with a GluN1 ligand
for 5 s with a 3-s interval between pulses. The GluN1 ligands tested were glycine, 1 mM;
D-serine,

1 mM; L-alanine, 15 mM; ACBC, 10 mM; and DCKA, 100 μM to match the MFD
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experiments. Cells were held at −60 mV. All recordings were performed using an
Axopatch 200B amplifier (Molecular Devices), acquired at 10 kHz using pCLAMP10
software (Molecular Devices) and filtered online at 5 kHz. All experiments were
performed at room temperature.

Accessible Volume (AV) simulations to estimate measured distance
The accessible volume considers the dyes as hard sphere models connected to
the protein via flexible linkers (modeled as a flexible cylindrical pipe) (121, 143, 171,
172). The overall dimension (width and length) of the linker is based on their chemical
structures. For Alexa 488 the five-carbon linker length was set to 20 Å, the width of
the linker is 4.5 Å, and three dye radii 5.0, 4.0, and 1.5 Å. Similarly, for Alexa 647 the
dimensions used were: length = 22 Å, width = 4.5 Å and the three dye radii 11.0, 3.0,
and 1.5 Å.
To account for dye linker mobility we generated AVs for donor and acceptor
dyes attached to the LBD by in silico labeling at Ser-507 and Thr-701. For this pair of
AVs, we calculated the distance between dye mean positions (Rmp),
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where R D and R A are all the possible positions that the donor and acceptor
fluorophores can take. However, in intensity based measurements, the mean donoracceptor distance is determined by the integration time and Rmp cannot be
experimentally determined; thus, the effective and experimentally determined
distance becomes,
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the relationship between Rmp and 〈RDA〉E can be derived empirically following a third
order polynomial from many different simulations.

MFD for smFRET experiments
MFD for confocal smFRET studies of single molecules was done using PIE (173)
with two diode lasers (model LDH-D-C-485 at 485 nm and laser LDH-D-C-640 at 640
nm; PicoQuant, Germany) operating at 40 MHz with 25-ns interleaved time. The
power at objective was set for 120 microwatts for the 485-nm laser line and 39
microwatts for the 640 nm excitation. Freely diffusing doubly labeled LBD molecules
are excited as they pass through the focal point of a ×60, 1.2 NA collar (0.17) corrected
Olympus objective. The emitted fluorescence signal was collected through the same
objective and spatially filtered using a 70-μm pinhole to define an effective confocal
detection volume. The emitted fluorescence was divided into parallel and
perpendicular polarization components at two different spectral windows (“green” and
“red”) through band pass filters, ET525/50 and ET720/150, for green and red,
respectively (Chroma Technology Co.). In total, four photon detectors are used: two
for green (PMA hybrid model 40 PicoQuant) and two for red channels (PMA hybrid
model 50, PicoQuant). A TCSPC module (HydraHarp 400, PicoQuant) with timetagged time-resolved mode and 4 synchronized input channels were used for data
registration.
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For smFRET measurements donor-acceptor (DA)-labeled LBD samples were
diluted to a picomolar concentration in PBS buffer (50 mM sodium phosphate, pH 7.5,
150 mM NaCl), which had been charcoal filtered to remove residual impurities. At
picomolar concentrations we assure that we observe ∼1 molecule/s. To prevent
adsorption artifacts, NUNC chambers (Lab-Tek, Thermo Scientific, Germany) were
pre-coated with a solution of 0.01% Tween 20 (Thermo Scientific) in water for 30 min
and then rinsed with ddH2O. Collection time varied from several minutes up to 2 h.
Standard controls consisted of measuring water to determine the instrument response
function, buffer for background subtraction and the nanomolar concentration of
green and red standard dyes (Rhodamine 110, Rhodamine 101, and Alexa 647) in water
solutions for calibration of green and red channels, respectively. To calibrate the
detection efficiencies we used a mixture solution of double labeled DNA
oligonucleotides with known distance separation between donor and acceptor dyes.
Ligands used were glycine, 1 mM; D-serine, 1 mM; L-alanine, 15 mM; ACBC, 10 mM; or
DCKA 100 μM.

MFD histograms and FRET lines
Bursts were selected by 2σ criteria out of the mean background value with cutoff times that vary from sample to sample with a minimum of 60 photons for each
burst (174). Each burst was then processed and fitted using a maximum likelihood
algorithm and previously developed programs (LabVIEW, National Instruments Co.)
(175). Bursts were selected according to the following rules: the difference in burst
duration on green channels given donor excitation (TGX) and burst duration on red
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channels given direct acceptor excitation (TRR) was −1.5 ms <TGX − TRR < 1.5 ms; and
bursts satisfy the FRET stoichiometry (SPIE) parameter of 0.13 < SPIE < 0.6, which
selects for bursts with both fluorophores present. Fluorescent bursts were plotted in
two-dimensional histograms (Origin 8.6, OriginLab Co.).
The relationship between the ratio of the donor fluorescence over the acceptor
fluorescence FD/FA and the fluorescence-weighted lifetime obtained in burst analysis
〈τD(A)〉f depends on specific experimental parameters such as fluorescence quantum
yields of the dyes (ΦFD(0) and ΦFA for donor and acceptor, respectively), background
(〈BG〉 and 〈BR〉 for green and red channels, respectively), detection efficiencies (gG and
gR for green and red, respectively), and cross-talk (α). The parametric line that relates
two FRET indicators (FD/FA and 〈τD(A)〉f) was introduced by Seidel's group and is
defined as,
−1

𝛷𝐹𝐷(0)
𝜏𝐷(0)
𝐹𝐷
( )
=
∙(
− 1)
𝑖
𝐹𝐴 𝑠𝑡𝑎𝑡𝑖𝑐
𝛷𝐹𝐴
∑3𝑖=0 𝐴𝑖 (〈𝜏𝐷(𝐴) 〉𝑓,𝐿 )
Where Ai are the coefficients of an empirical polynomial function that takes into

(13)

account the intrinsic linker dynamics of the dyes. FRET lines are used to identify static
or slowly exchanged limiting populations.

Quantum yields
The donor and acceptor quantum yields were corrected due to the presence of
different ligands and need to be corrected accordingly. We assumed that only
dynamic quenching takes place and that ΦFD(0), ΦFA are proportional to the speciesaveraged fluorescence lifetime 〈τD(A)〉x of donor or acceptor, respectively. As reference
samples we used Alexa 488-labeled DNA 〈τD(0)〉x = 4.0 ns, ΦFD(0) = 0.8 and for the
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acceptor we used Cy5-labeled DNA with 〈τA〉x = 1.17 ns and ΦFA = 0.32 (176). The
obtained donor and acceptor quantum yields are presented in Table 10. This FRET
pair has a reduced Förster distance of 52 Å where we assumed isotropic reorientation
of the dyes using κ2 = 2/3 due to the long linkers.

Table 10. Quantum Yields were estimated as described in Appendix
Sample

ΦFD(0)

ΦFA

Gly

0.773

0.42

D-Ser

0.828

0.43

L-Ala

0.843

0.41

ACBC

0.799

0.38

DCKA

0.850

0.40

κ2 = 2/3 Assumption, 〈κ2〉, and κ2 Distributions
Experimentally, one can test whether assuming κ2 = 2/3 is justifiable or not.
Considering that fluorophores follow the “wobble in a cone” model (177), it is possible
to calculate a distribution of all possible values of κ2. For that, we determined the
residual anisotropies (r∞) (D only, donor; A, acceptor, and A(D), the sensitized by

110

FRET emission of acceptor) from single molecule experiments. We consider the
extreme limit when 〈rss〉 ≅ r∞. Then, all κ2 values will follow (143),
𝜅2 =

2 2 (2) (2)
2 (2)
+ 𝑆𝐷 𝑆 (𝛽1 ) + 𝑆𝐴 𝑆 (2) (𝛽2 )
3 3
3
𝑆 (2) (𝛿) + 6𝑆 (2) (𝛽1 )𝑆 (2) (𝛽2 )
2 (2) (2)
+ 𝑆𝐷 𝑆𝐴 (+1 + 2𝑆 (2) (𝛽1 ) + 2𝑆 (2) (𝛽2 ))
3
−9 cos 𝛽1 cos 𝛽2 cos 𝛿

(14)

where, β1 and β2 are the angles between the symmetry axes of the dyes rotations,

and δ is the angle between the symmetry. The necessary second-rank order
parameters S(2) are defined by,
𝑟𝑠𝑠,𝐴(𝐷)
1
𝑆 (2) (𝛿) = (3 cos 2 𝛿 − 1) =
(2) (2)
2
𝑟0 𝑆 𝑆
𝐷

𝐴

1
𝑆 (2) (𝛽1 ) = (3 cos 2 𝛽1 − 1)
2

(15)

1
𝑆 (2) (𝛽2 ) = (3 cos 2 𝛽2 − 1)
2
where r0 is the fundamental anisotropy of the dyes whose values were 0.38 and 0.39
for the donor and acceptor fluorophores, respectively. The dye motions are
characterized by the second-rank order parameters SD(2) and SA(2) by Equation 16

Donor
Acceptor

𝑟𝑠𝑠,𝐷−𝑜𝑛𝑙𝑦
1
(2)
cos 2 𝜃𝑑𝑖𝑠𝑘 = √
= −𝑆𝐷
2
𝑟0
1
𝑟𝑠𝑠,𝐴
(2)
cos 𝜃𝑐𝑜𝑛𝑒 (1 + cos 𝜃𝑐𝑜𝑛𝑒 ) = √
= 𝑆𝐴
2
𝑟0

From all possible orientations and combinations a κ2- distribution and its
corresponding arithmetic mean (〈κ2〉) can be determined and compared with the
assumed to κ2 = 2/3.
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(16)

Probability distribution analysis (PDA)
To model the shape of the FD/FA distributions we use probability distribution
analysis or PDA (140, 178). In short, the measured fluorescence signal (S), consisting of
fluorescence (F), and background (B) photons are expressed in photon count numbers
per time window (Δt) of a fixed length. In multiparameter fluorescence detection the
signal is split into two spectral windows termed “green” and “red” each with two
polarization components (parallel “‖” and perpendicular “⊥”). The probability of
observing a certain combination of photon counts in two detection channels 1 and 2
(e.g. 1 = green and 2 = red) and measured by two or more single-photon counting
detectors, P(S1,S2), is given by a product of independent probabilities,
𝑃(𝑆1 , 𝑆2 ) =

𝑃(𝐹) 𝑃(𝐹1 , 𝐹2 |𝐹)𝑃(𝐵1 )𝑃(𝐵2 )

∑
𝐹1 +𝐵1 =𝑆1 ;𝐹2 +𝐵2 =𝑆2

(17)

P(F) describes the fluorescence intensity distribution, i.e. the probability of observing
exactly F fluorescence photons per time window (Δt). P(B1) and P(B2) represent the
background intensity distributions. P(F1,F2|F) is the conditional probability of
observing a particular combination of F1 and F2, provided the total number of
fluorescence photons is F. This can be expressed as,
𝑃(𝐹1 , 𝐹2 |𝐹) =

𝐹!
𝐹!
𝑝1 𝐹1 𝑝2 𝐹2 =
𝑝 𝐹1 (1 − 𝑝1 )𝐹−𝐹1
𝐹1 ! 𝐹2 !
𝐹1 ! (𝐹 − 𝐹1 )! 1

(18)

where p1 stands for the probability of a detected photon to be registered by the first
detector (e.g. green in a FRET experiment). For smFRET, p1 is unambiguously related
to the FRET efficiency E according to,
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−1

𝐸𝛷𝐹𝐴
𝑝1 = (1 + 𝛼 +
)
(1 − 𝐸)𝐺𝛷𝐹𝐷(0)
𝑝2 = 1 − 𝑝1

(19)

here, G stands for the ratio of the detection efficiencies in the spectral windows (G =
gG/gR). The quantum yields (ΦFD(0) and ΦFA) were previously defined, and α is the
spectral cross-talk.
The distribution P(F) in Equation 17 is not directly measurable; instead, the
total signal intensity distribution P(S) is measured, which is given by,
𝑃(𝑆) = 𝑃(𝐹) ⊗ 𝑃(𝐵)

(20)

where P(B) is the distribution probability of background counts. Details on the
deconvolution procedure are described elsewhere (140). Finally, Equation 19 can be
extended for multiple species with the brightness correction used in this work (179).
Each species distribution has a half-width (hwDA), which depends mostly in shot noise
and photophysical properties of the acceptor fluorophore, and it was fixed to 6% of
the 〈RDA〉E.

Generation of smFRET constructs for TMD measurements
Wild-type GluN1-1a and GluN2A plasmids in pcDNA3.1 were kindly provided
by Shigetada Nakanishi (Osaka Bioscience Institute, Osaka, Japan). All mutations were
introduced using standard PCR-based mutagenesis methods. To create the
background constructs, non-disulfide-bonded cysteines at sites 15 and 22 in GluN1 and
231, 399, and 460 in GluN2A were mutated to serines, resulting in GluN1* and
GluN2A*. In order to label these receptors, a reactive cysteine was mutated to replace
the native phenylalanine at site 554 in GluN1*.
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Electrophysiology for TMD measurements
HEK293T cells were plated into 30 mm dishes and transfected (jetPrime,
PolyPlus) with GluN1*F554C and GluN2A* constructs at a mass ratio of 1.5:4.5 μg per
20 ml of media. 300 μM DL-AP5 (abcam) and 30 μM DCKA (abcam) were present in
the media and recordings were performed 24 to 48 hours post-transfection. Prior to
recording, cells were incubated in 150 nM Alexa 555 maleimide (ThermoFisher) and
600 nM Alexa 647 maleimide (ThermoFisher) for at least 1 hour to mimic smFRET
labelling conditions. Outside-out patches were excised and piezo-driven solution
exchange was performed as outlined elsewhere (180). The external solution was (in
mM) 150 NaCl, 20 HEPES, 10 Tricine, 1 CaCl2, and 0.1 glycine, pH 7.4 (NaOH). The
pipette solution was 135 CsF, 33 CsOH, 11 EGTA, 10 HEPES, 2 MgCl2 and 1 CaCl2, pH
7.4. Lifted whole cell recordings were performed as described elsewhere(122) using the
same solutions as above with the addition of 2.5 mM KCl to the external solution.

Single molecule FRET sample preparation for TMD measurements
HEK293T cells were transiently transfected with GluN1*F554C and GluN2A*
DNA at a mass ratio of 2.5:7.5 μg per 10 cm dish. 300 μM DL-AP5 (abcam) and 30 μM
DCKA (abcam) were present during transfection to limit excitotoxicity. One day posttransfection, cells from two 10-cm dishes were harvested and labeled for 1 hour at
room temperature with 150 nM of donor fluorophore Alexa 555 maleimide
(ThermoFisher) and 600 nM of acceptor fluorophore Alexa 647 maleimide
(ThermoFisher) in 3 mL extracellular buffer. After washing, labeled cells were then
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solubilized for 1 hour at 4°C in buffer containing phosphate-buffered saline, 1% lauryl
maltose neopentyl glycol (Anatrace), 2 mM cholesteryl hydrogen succinate (MP
Biomedicals), and protease inhibitor (Pierce). Unsolubilized debris were then spun
down for 1 hour at 100,000 × g at 4°C, and the supernatant used as the smFRET
sample.

Flow chamber preparation for TMD measurements
Plasma cleaned glass coverslips (22 × 22 mm No. 1) were aminosilanized
through Vectabond treatment (Vectabond in acetone 2% v/v; Vector Laboratories,
Burlingame, CA). Silicone templates (Grace bio-Labs) were used to treat a small
section of the coverslips with a PEG solution containing 5kDa biotin-terminated PEG
(2.5% w/w in molecular biology grade (MB) water, NOF Corp.), and 5kDa mPEG
succinimidyl carbonate (25% w/w in MB water, Laysan Bio Inc.) in 0.1M sodium
bicarbonate (Sigma-Aldrich). The coverslips were then left to incubate in a dark and
moist environment overnight. On the day of the experiment, the coverslips were
treated with another round of PEGylation with a short chain 333 Da NHS-ester PEG
(Thermo Scientific) and incubated for 2-3 hrs. After washing off excess PEG, the
coverslips were dried with a mild flow of nitrogen. Custom hybriwell chambers (Grace
bio-Labs) with dual silicon press-fit tubing connectors (Grace bio-Labs) were placed
atop the coverslips to construct a flow chamber.
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Protein preparation and attachment to coverslips for TMD measurements
Streptavidin in buffer solution containing Phosphate Buffered Saline (PBS),
1mM DDM (n-dodecyl-β-D-maltoside) and 0.2 mM CHS (cholesteryl hemisuccinate),
were introduced through the flow chamber and incubated for 10 minutes. 10 nM of
biotinylated goat Anti-Mouse IgG (H+L) secondary antibody (Jackson Immuno
Research Laboratories, Inc.) was then flowed into the chamber and incubated for 2030 minutes. Next, 10 nM of anti-NMDAR mouse monoclonal primary antibody
(Abcam Inc.) was flowed in. After each antibody addition, the chamber was flushed
with buffer to get rid of the unbound antibodies. All dilutions were made in PBS buffer
with 1 mg/mL Bovine serum albumin (Sigma-Aldrich).
Meanwhile, whole cells expressing NMDA receptors were labeled with donor
and acceptor fluorophores for 1 hour at room temperature. The cells were then lysed
and the membrane proteins solubilized with 1% MNG-3. Intact NMDA receptors were
then attached to a glass slide for FRET data acquisition using in situ
immunopreciption (SiMPull (152)) by passing the solubilized protein through the
chamber in three 60 μL shots and incubating for 20-30 minutes before flushing the
chamber with buffer containing Phosphate Buffered Saline (PBS), 1mM DDM (ndodecyl-β-D-maltoside) and 0.2 mM CHS (cholesteryl hemisuccinate).
Control slides using unmutated GluN1*/GluN2A* receptors showed minimal
background labeling, while slides prepared with GluN1*F554C/GluN2A* showed
isolatable single molecules exhibiting fluorescence and energy transfer (Figure 16).
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smFRET data acquisition for TMD measurements
Acquisition was performed as above; however, ligands—1 mM glutamate, 1 mM
glycine, 1 μM MK-801, and/or 10 μM Zn2+—were added to the ROXS to achieve the
liganded conditions necessary for each TMD experiment. Additionally, 10 mM tricine
was included to chelate any unbound zinc ions under the apo, desensitized, and openstabilized conditions. Step Transition and State Identification (STaSI) analysis (89,
153) was run for each sample to obtain an unbiased determination of number and the
identification of discrete conformational states within each sample(89, 90, 132, 133,
137, 152, 153).

Free energy calculations
For each liganded condition, the free energy of the most populated STaSIidentified state was set to 0 kBT. The STaSI determined occupancies were then used to
calculate the equilibrium constant Keq between each pair of states, and the free energy
of every state relative to the most populated state was determined via the equation:
∆𝐺 0 = −𝑘𝑏 𝑇𝑙𝑛𝐾𝑒𝑞

(21)

The transition probabilities between each pair of states, given our 10 ms bin time, was
used to determine the reaction rate for each transition, and the heights of the energy
of activation barriers were calculated assuming a first-order reaction rate and the
Arrhenius equation:
𝑟𝑎𝑡𝑒 = 𝑘[𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑒]
𝑘 = 𝐴𝑒 −𝐸𝑎 ⁄𝑘𝐵 𝑇
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(22)

Concentration of the starting state was taken as the STaSI-derived fractional
occupancy of that state, and the value of the pre-exponential was chosen to be (10
ms)-1. Forward and reverse energies of activation were averaged in the final figure.
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